Molecular diagnostics market is projected to record significant gains over the forthcoming timeframe. Molecular diagnostics is one of the most transformative and dynamic areas of diagnostics, leading to various advancements in research and treatment which are revolutionizing healthcare throughout a wide array of medical conditions and diseases.

The term molecular diagnostics is a class of diagnostic tests that evaluate health of a person literally at a molecular level, measuring and detecting specific genetic sequences in RNA or DNA or the proteins they express.

Recent advances in molecular diagnostics are starting to shift from basic research to clinical reality. Some of the popular as well as cost-efficient diagnostic tests in medicine are based on quantification of a particular protein and are often used in hospitals globally.

Request sample copy of this report @ https://www.decresearch.com/request-sample/detail/434

Patients as well as families generally rely on molecular diagnoses for disease prognosis, family planning and health-care management, and they get benefits when an answer is found for the afflicting condition.

Based on the application landscape, the market is segmented into oncology testing, blood screening, genetic testing, and infectious disease. Among these, the genetic testing segment is projected to record a CAGR of around 11% between 2019 to 2020 owing to the increasing advancements in diagnostic tools enabling higher sensitivity and specificity.

Furthermore, genetic testing has grown from a niche field for rare disorders to a wide scope of applications for personal use and complex disease. Applications of clinical genetic testing range from medical disciplines, which includes carrier and diagnostic testing for inherited disorders; pharmacogenetic testing to guide individual drug selection, dosage and response; to screening of newborn for highly penetrant disorders; and pre-symptomatic and predictive testing for adult-onset and complex disorders.

Make Inquiry about this report @ https://www.decresearch.com/inquiry-before-buying/434

With respect to technology, the market is bifurcated into sequencing, isothermal amplification, PCR, chips & microarrays, in situ hybridization, mass spectrometry, and others. Among these, the in situ hybridization (ISH) segment is slated to record a market valuation of more than $3 billion by 2026, owing to the technological advancements that are allowing low cost gene mapping and diagnostics.

ISH is a technique allowing localization of a particular segment of nucleic acid within a histologic section. The fundamental basis of ISH is that nucleic acids if preserved effectively within a histologic specimen, could be discovered through the application of a corresponding strand of nucleic acid to which a reporter molecule is generally attached. The technique is specifically useful in neuroscience.

Other applications of ISH are microbiology, pathology, developmental biology, karyotyping, and phylogenetic analysis.

From a regional frame of reference, Latin America molecular diagnostics market is expected to reach a valuation of more than $1 billion by 2026, which is attributable to the rising awareness about cost-effective molecular diagnostics options among general population.

Molecular diagnostics has become an important part of disease management and therapy, used in applications areas like drug regimen selection, detection of predisposition to disease, patient stratification, toxicity avoidance, and therapeutic monitoring. This growing integrality of the industry is poised to help it grow significantly in coming years.

Read more here:
Molecular Diagnostics Market Detailed Analysis of Current Industry Figures with Forecasts Growth By 2025 - 3rd Watch News

Recommendation and review posted by Bethany Smith

Austin was three years old and Max was a newborn when their mother, Jenn McNary, learned they had a rare genetic condition called Duchenne muscular dystrophy. The doctor painted a grim picture: Her boys would stop walking by age 12 or 13 and, shortly thereafter, they would require nighttime ventilation. They would each need a tracheotomy, a feeding tube, or both by their late teens. Death would come a few years later.

It hasnt worked out that way, thanks to two new drugs that became available after the boys 2002 diagnosis. Exondys 51, a medicine that targets their genetic mutation, slows the diseases progression, and Emflaza, a corticosteroid, mitigates some of its symptoms. Thanks to these treatments, Austin now attends college and interns at a biotech company. Max attends his local high school in Newton, Massachusetts. Both are able to get around in wheelchairs, and neither needs ventilation. McNary just rented an apartment for her boys because they can function on their own with the help of an aide.

By all accounts, the drugs have been transformative, McNary said. But, she added, her boys arent going to be cured, and extending and improving their life for an unknown period of time comes at a high price. Emflaza came onto the market in 2017 at an annual cost of $65,000. Exondys 51 appeared in 2016 at $748,500. Neither of the drugs will help the young men walk again and, in the eyes of some U.S. health economists, the drugs are not worth the price.

Thats why McNary hates the quality-adjusted life year (QALY, pronounced qua-lee), an economic calculation that attempts to quantify the value of a medical intervention, based in part on the quality of life it bestows on recipients.

First developed by U.S. economists in the late 1960s and early 1970s, variations of the QALY have been used for years by governments around the world to help determine what treatments citizens can obtain under public health care. In Americas free-market health care system, however, QALY calculations have largely been avoided. As McNary and others like her are finding out, thats starting to change.

As policymakers and insurance companies scramble to get a handle on skyrocketing health care costs, they are promoting the idea of paying for value. In this view, drugs designated as higher-value should be prioritized over lower-value treatments. But this raises a thorny question: Who gets to define value? Health economists and insurance companies who seek to use limited health care dollars judiciously? Or patients, parents, and doctors who want to receive the best health care for their situation?

Because the quality-adjusted life year threatens her sons ability to get the medicine they need, McNary is clear about her answer. To me, the QALY is a measurement that says that keeping my sons alive by providing incremental benefit but not totally curing them is never going to be valuable, McNary said. Just mull that around in your head if you are less than perfect, you are worth less money.

In QALY math, a year of perfect health is equal to 1; death equates to 0. The value of other health states is derived from surveys of patients, caregivers, or the general public. Paralysis might be valued at .35, for example, and mild Alzheimers disease at .52, depending on the survey. Those numbers can then be plugged into a formula that allows the relative cost-effectiveness of treatments to be compared to identify the best buys.

Economists developed the QALY concept more than 40 years ago to address a fundamental question: Where should we spend whose money to undertake what programs to save which lives with what probability? Richard J. Zeckhauser and Donald Shepard asked in a 1976 article describing the basic QALY formula. The next year, as U.S. health care spending topped $120 billion, Harvard health policy professor Milton C. Weinstein and his colleague, cardiologist William B. Stason, sounded an alarm bell. It is now almost universally believed that the resources available to meet the demands for health care are limited, they wrote in the New England Journal of Medicine. We, as a nation, will have to think very carefully about how to allocate the resources we are willing to make available for health care.

Their article cited by other authors more than a thousand times in the past four decades pointed out that resources were already being allocated by millions of individual decisions: hospitals rationing beds where they didnt have room for all patients, for example, and insurers agreeing to pay for some tests and treatments but not for others. Such decisions, they argued, were often inconsistent with the societal objective of deriving the maximum health benefits from the dollars spent, an objective that could be achieved by putting the QALY to work.

In the intervening decades, some countries the United Kingdom, the Netherlands, and Sweden, for example have embraced QALY-based evaluations. In the U.K., cost-effectiveness studies are used, in part, to determine which therapies the National Health Service will provide for residents. The publicly-funded health system does not cover Orkambi, the first cystic fibrosis treatment that targets the cause of the disease, for example, because its cost-per-QALY far exceeds the U.K. cost-effectiveness threshold.

In the United States, however, QALY-based assessments have not gained traction until recently. Perhaps the general reason is that we as patients and our providers dont want to be limited in the treatment options available, said Louis P. Garrison Jr., an economist in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington.

In fact, QALY-based cost-effectiveness reviews are so controversial that the federal government has repeatedly quashed their use. In 1992, the Department of Health and Human Services rejected Oregons attempt to use QALY-based cost-effectiveness assessments to determine what services its Medicaid program would cover. In 2010, as part of the Patient Protection and Affordable Care Act, Congress prohibited the use of QALYs by the Medicare program. It also banned the federal Patient-Centered Outcomes Research Institute from using QALY thresholds in its assessments of comparative treatments.

But more than half of U.S. residents are covered by private insurance companies, which are not prohibited from using QALY-based assessments to decide which medicines they will cover for their members. Traditionally, however, private insurers have generally not used QALYs explicitly in their decisions about what tests and treatments they will pay for, according to a recent report by the National Council on Disability. Instead, when major U.S. insurers decide to limit access to a given medication, they usually cite insufficient data to justify its use in a given situation.

Indeed, until recently, U.S. insurers did not have a source for QALY-based cost-effectiveness reports. That began to change in 2014, when the Institute for Clinical and Economic Review, a nonprofit research organization based in Boston, turned its attention to high-cost drugs. Founded in 2006 as a research project based at Harvard Medical School, ICER initially issued reports on broad topics such as obesity management and palliative care. But when Sovaldi, a drug for deadly hepatitis C, came on the market at the then-shocking price of $84,000 for a 12-week course of treatment, ICER kicked into action. Despite the high price, its assessment found that Sovaldi is cost-effective for some patients. Insurers took notice.

Since then, the organization has been churning out several drug-assessment reports each year. Each report includes its opinion of how much the drug is worth; drugs priced higher than that are deemed not cost-effective. ICER has no authority over anyone, but its reports have become popular reading for U.S. insurers. If there is a drug of note being approved by the FDA, theres also likely going to be an ICER assessment of that drug that can factor into their decision-making, said David Whitrap, the research organizations vice president of communications and outreach.

U.S. health care spending has risen dramatically since Weinstein and Stason expressed concern in the mid-1970s. In 2016, the U.S. spent nearly 18 percent of its gross domestic product on health care, far outstripping the average of 11 percent for 10 other high-income nations. High prices for prescription drugs is one reason. Were seeing price tags now of $1 million, $2 million, said Seema Verma, administrator for the federal Centers for Medicare and Medicaid Services, at a conference recently. Thats completely unsustainable for the system.

Thats why Peter Neumann, director of the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, said cost-effectiveness analyses are needed more than ever. But there are many reasons for the resistance, Neumann and his co-authors wrote in the Journal of the American Medical Association, including an inclination on the part of many individuals in the United States to minimize the underlying problem of resource scarcity and the consequent need to explicitly ration care.

Further, Ari Neeman, a disability rights activist and consultant to Partnership to Improve Patient Care, a coalition of advocacy groups, said the idea that two health conditions can be numerically compared to one another is simply wrong. Proponents of the QALY will say it is this mathematically perfect measure that gives us a superpower ability to compare depression drugs to cystic fibrosis drugs to cancer drugs even though all of those drugs do different things because it lets you translate them back to this common measure, he said. Our concern is that when you engage in that process of translation, you lose some significant nuance in terms of the amount of benefit thats being delivered.

The Partnership argues the QALY calculation is flawed because it assumes quality of life can be captured by a certain number, despite the fact that different surveys arrive at different numbers. For example, a 2006 quality-of-life survey in the U.S. assigns blindness/low vision as .69 on the 0-to-1 scale, while a 2011 survey in the U.K. gives blindness/low vision a score of .78.

Beyond the methodological issues, Neeman said, there are all kinds of ethical problems with it. People with disabilities and chronic medical conditions may value a treatment that offers an incremental improvement in the quality or length of their lives, even though the QALYs gained are less than those for a treatment that prevents the loss of perfect health.

Former U.S. Representative Tony Coelho, a Democrat from California and a primary author of the Americans with Disabilities Act, is the Partnerships chairman. I worry that more focus is being given to what is most cost-effective for the average patient than creating a system that works for each individual patient, he wrote in 2018. The medication I take for epilepsy isnt high value for every patient. But its the only one that works for me.

Thats why, Neeman said, cost-effectiveness analyses must consider the fact that not all patients respond the same way to a drug. Some patients need drugs that arent deemed cost-effective for the general population. Its important to account for that, he said. Otherwise were giving insurers a tool to deny care to people who need it.

When an insurer decides to cover a specific drug, that decision affects everybody who pays into the insurance pool. Michael Sherman, chief medical officer for the insurer Harvard Pilgrim Health Care, uses the example of a gene therapy that costs $1 million to treat a child who will die without it. Under the ACA, families will hit their out-of-pocket maximum at about $16,000, and many health plans have out-of-pocket maximums far below that. The rest of that million dollars is going to be paid by everyone else thats the way it works in insurance, he said. When insurers see that kind of unanticipated budget impact, they raise premiums or out-of-pocket cost-sharing for everyone.

Like other proponents of the QALY, Neumann sees it as an imperfect but useful tool. Any single number is never going to capture everything, he said.

The problem is, if youre not going to use QALYs, what are you going to use?

Thats an urgent question, particularly now when there is a huge pipeline for rare-disease therapies, often called orphan drugs. By 2024, orphan drug sales are expected to reach $242 billion.

In the U.S., a rare disease is defined as one that affects fewer than 200,000 people. While these conditions are individually rare, in the aggregate, an estimated 25 to 30 million Americans thats about one in 10 live with a rare disease. Most rare diseases affect children, and many are fatal or disabling.

Historically, drugmakers spent little effort developing treatments for rare diseases, but that changed with the passage of the Orphan Drug Act of 1983, which provides tax credits and a seven-year marketing exclusivity to companies that develop rare-disease treatments. Hundreds of such treatments have won FDA approval in recent years, with more than 560 medicines in the works.

Those treatments are generally expensive. On average, the per-patient cost for orphan drugs in the U.S. is almost 4.5 times more than for non-orphan drugs.

In the two decades ending in 2017, the average annual cost for orphan drugs was $123,543, based on the price at the time the drug launched, compared to $4,961 for traditional drugs. For Duchenne alone, more than 30 orphan therapies are in development. None of them are going to cure patients, McNary said. But she hopes new treatments, generally used in combination, will help her sons live longer, healthier lives and completely change the disease trajectory for younger patients whose disease has not yet progressed as far.

The barrier she worries about is cost-effectiveness analysis. In August, the Institute for Clinical and Economic Review published its assessment of treatments for Duchenne, which affects about 400 to 600 boys born in the U.S. each year. Emflaza, the corticosteroid, appears to be as good as or better than prednisone, another corticosteroid approved to treat the disease, but it would need a price cut of at least 73 percent to be considered cost-effective.

Exondys 51 approved by the FDA for about 13 percent of the Duchenne population got a worse review. In the clinical trials used to seek FDA approval, no clinical benefit, including motor function improvement, was demonstrated. (The FDA approved the drug because some of the patients treated with Exondys 51 had a slight increase in dystrophin levels in skeletal muscle.) In light of that, Exondys 51 was not deemed cost-effective at any price.

But Jenn McNary said the drug works for her sons. Austin, who was not eligible for the Exondys 51 clinical trial, stopped walking at age 10. Max got in the trial and started taking the drug at age 9.They have the same mutation, they have been raised by the same mother, so one would expect they would progress similarly, she said. But Max walked until he was 17.

Austin was already in a wheelchair when, at age 15, he started taking Exondys 51. He regained some upper-body strength that changed his life, according to his mother. Hes able to use a urinal on his own, which makes is possible for him to have a job and to go to college without an aide, she said.

The Medicaid program in Massachusetts, where the McNarys live, wont pay for Maxs Duchenne therapies. For the time-being, the drugmakers are giving him the drugs free through a patient-assistance program. Austin, because hes enrolled in college, is eligible for student coverage through Blue Cross Blue Shield of Massachusetts. The insurer, by policy, does not cover Exondys 51 for patients who can no longer walk. His mother appeals the insurance denial. Every six months, she sends a video of Austin in action, along with a letter from his doctor and so far, his medicines have been covered.

The payers made their coverage policies before the quality-adjusted life year analysis was published. Now, insurers who have been covering the Duchenne treatments have an independent analysis with which to rethink that decision.

For now, there is one thing that QALY supporters and critics agree on. Very promising drugs are coming, and theyre going to be very expensive, said Neumann, the health economist at Tufts. Increasingly, the QALY appears poised to influence how American health care money is spent.

Lola Butcher is a health care business and policy writer based in Missouri. Follow her on Twitter @LolaButcher

This article was originally published on Undark and has been republished here with permission. Undark can be found on Twitter @undarkmag

Read the original post:
What's a life worth in dollars and cents? Should that influence who gets treated for expensive disease treatments? - Genetic Literacy Project

Recommendation and review posted by Bethany Smith

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Phesgo, a fixed-dose combination (FDC) of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (SC, under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Genentech has combined two monoclonal antibodies that can be administered by a single SC injection.

The FDA approval of Phesgo reflects our commitment to improving outcomes for the many people living with HER2-positive breast cancer, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. Phesgo offers a treatment administration that supports the needs and preferences of individual patients, and helps to meet the increasing demand across the healthcare system for faster and more flexible treatment options.

Phesgo is available in one single-dose vial. Administration can take approximately eight minutes for the initial loading dose and approximately five minutes for each subsequent maintenance dose. This is compared to approximately 150 minutes for infusion of a loading dose of Perjeta and Herceptin using the standard IV formulations, and between 60-150 minutes for subsequent maintenance infusions of the two medicines. Phesgo can be administered by a healthcare professional in a treatment center or at a patients home.

The approval is based on results from the pivotal Phase III FeDeriCa study, which met its primary endpoint with Phesgo showing non-inferior levels of Perjeta in the blood during a given dosing interval (Ctrough) when compared to IV administration of Perjeta. The safety profile of Phesgo with chemotherapy was comparable to IV administration of Perjeta plus Herceptin and chemotherapy, and no new safety signals were identified, including no meaningful difference in cardiac toxicity. The most common adverse events in both arms were alopecia, nausea, diarrhea and anemia.

The Phase II PHranceSCa study showed that 85% (136/160) of people receiving treatment for HER2-positive breast cancer preferred treatment under the skin to IV administration due to less time in the clinic and more comfortable treatment administration.

For those who qualify, Genentech will offer patient assistance programs for people prescribed Phesgo by their doctor through Genentech Access Solutions. Please contact Genentech Access Solutions at (866) 422-2377 or visit http://www.Genentech-Access.com for more information.

About the FeDeriCa study

FeDeriCa is an international, multi-center, two-arm, randomized, open-label, Phase III study evaluating the pharmacokinetics, efficacy, and safety of SC injection of Phesgo in combination with chemotherapy, compared with standard IV infusion of Perjeta and Herceptin in combination with chemotherapy, in 500 people with HER2-positive EBC who are being treated in the neoadjuvant (before surgery) and adjuvant (after surgery) settings. The primary endpoint of the study is minimum levels of Perjeta in the blood during a given dosing interval (Ctrough). Secondary endpoints include safety; minimum levels of Herceptin in the blood during a given dosing interval (Ctrough); and total pathological complete response, meaning there is no tumor tissue detectable in the tissue removed at the time of surgery. The safety profile of Phesgo was comparable with that of Perjeta and Herceptin administered intravenously.

Data from the FeDeriCa study were presented at the San Antonio Breast Cancer Symposium in December 2019. The FeDeriCa study met its primary endpoint of non-inferior levels of Perjeta in the blood. The geometric mean ratio (GMR; a type of average used when assessing pharmacokinetics) for the primary endpoint was 1.22 (90% CI: 1.14 to 1.31), with the lower limit of the 90% CI of the GMR=1.140.80 (the pre-specified non-inferiority margin). A secondary endpoint of non-inferior levels of Herceptin was also met, with blood concentrations for people receiving the fixed-dose combination non-inferior to those receiving IV Herceptin (GMR=1.33 [90% CI: 1.24 to 1.43]; lower limit of 90% CI of GMR=1.240.80). A non-inferiority endpoint was chosen for the study to ensure that people were receiving sufficient dosing with Perjeta and Herceptin as compared to the established IV doses at the same treatment intervals.

About the PHranceSCa study

PHranceSCa is a randomized, multi-center, multinational, open-label, cross-over Phase II study evaluating patient preference for and satisfaction with subcutaneous (SC) administration of Phesgo. All patients completed neoadjuvant treatment with Perjeta, Herceptin and chemotherapy and had surgery before randomization. The primary endpoint of the study is the percentage of participants who indicate that they prefer treatment with Phesgo compared to the standard intravenous (IV) formulations of Perjeta and Herceptin. Secondary endpoints include participant-reported satisfaction and health-related quality of life outcomes; healthcare professionals' perceptions of time and resource use and convenience compared with IV formulations; as well as the safety and efficacy of each study regimen.

About HER2-positive breast cancer

Breast cancer is one of the most common cancers among women worldwide. According to the American Cancer Society, close to 280,000 people in the United States will be diagnosed with breast cancer, and more than 42,000 will die from the disease in 2020. Breast cancer is not one, but many diseases based on the biology of each tumor. In HER2-positive breast cancer, there is excess HER2 protein on the surface of tumor cells. Approximately 15-20% of breast cancers are HER2-positive based on the result of a diagnostic test.

About Phesgo

Phesgo (subcutaneous Perjeta and Herceptin) is a new fixed-dose formulation of Perjeta and Herceptin with Halozyme Therapeutics Enhanze drug delivery technology.

Trastuzumab in Phesgo is the same monoclonal antibody as in IV Herceptin and pertuzumab in Phesgo is the same monoclonal antibody as in IV Perjeta. The mechanisms of action of Perjeta and Herceptin are believed to complement each other, as both bind to the HER2 receptor, but to different places. The combination of Perjeta and Herceptin is thought to provide a more comprehensive, dual blockade of HER signaling pathways, thus preventing tumor cell growth and survival.

Halozymes Enhanze drug delivery technology may enable and optimize SC drug delivery for appropriate co-administered therapeutics. The technology is based on a proprietary recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily degrades hyaluronan a glycosaminoglycan or chain of natural sugars in the body, to aid in the dispersion and absorption of other injected therapeutic drugs.

Phesgo Indications and Important Safety Information

Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:

Phesgo is also approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

Important Safety Information

What should patients know about side effects with Phesgo?

Most serious side effects with Phesgo

Phesgo may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

Receiving Phesgo during pregnancy can result in the death of an unborn baby and birth defects.

Phesgo may cause serious lung problems.

Who should not receive Phesgo?

Other possible serious side effects

Most common side effects

The most common side effects of Phesgo when given with chemotherapy as part of an early breast cancer regimen are:

The most common side effects of Phesgo when given with docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:

Patients are encouraged to report side effects to Genentech and the FDA. Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at 1-888-835-2555.

Patients should talk to a healthcare professional for more information about the benefits and risks of Phesgo.

Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.

If a patient cannot afford their medication, visit http://www.genentech-access.com/patient for financial assistance information.

About Expanded Access Treatment Protocol for Continuity of Care During COVID-19

Genentech launched an expanded access treatment protocol in the United States, where the FDC of Perjeta and Herceptin is administered at home by a home health nursing provider. The study will continue beyond approval, aiming to help continuity of care during the COVID-19 pandemic for certain patients with HER2-positive breast cancer who have completed chemotherapy concurrent with Perjeta and Herceptin intravenously and are currently receiving or will be receiving Perjeta and Herceptin alone. To learn more, please visit here.

About Genentech Access Solutions

Access Solutions is part of Genentechs commitment to helping people access the Genentech medicines they are prescribed, regardless of their ability to pay. The team of in-house specialists at Access Solutions is dedicated to helping people navigate the access and reimbursement process, and to providing assistance to eligible patients in the United States who are uninsured or cannot afford the out-of-pocket costs for their medicine. To date, the team has helped more than 2 million patients access the medicines they need. Please contact Access Solutions (866) 4ACCESS/(866) 422-2377 or visit http://www.Genentech-Access.com for more information.

About Genentech in breast cancer

Genentech has been advancing breast cancer research for more than 30 years with the goal of helping as many people with the disease as possible. Our medicines, along with companion diagnostic tests, have substantially improved outcomes for HER2-positive breast cancer. As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for other subtypes of the disease, including triple-negative and hormone receptor-positive.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005687/en/

Follow this link:
FDA Approves Genentech's Phesgo (Fixed-dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-positive Breast Cancer -...

Recommendation and review posted by Bethany Smith

The unwanted side effects include blisters, scabbing, hyperpigmentation, and hypopigmentation. Of some comfort: Pigmentation issues aren't always permanent. If you get it, let your doctor know right away and use a little cortisone 1% cream on the area, says Marmur. Keep it out of the sun and heat, and apply a cool compress ASAP.

If you're predisposed to hyperpigmentation, your dermatologist may even make a preemptive strike. For patients with darker skin types, we apply over-the-counter hydrocortisone 1% cream in the office to minimize inflammation and the risk of darkening of skin, or post-inflammatory hyperpigmentation," says Kim. "We recommend applying the cream twice daily to the affected areas for three to five days.

It largely varies, since the lasers themselves have gotten better over the years. I've had patients who were able to tolerate the treatment without any numbing, and patients who experienced some pain even with topical anesthesia, says Kim. (I, a baby, prefer to spend an hour with numbing cream and have never felt a thing.)

Marmur compares the laser beam to a zinging feeling, similar to a needle prick. She's a fan of contact cooling systems, as they blunt the heat created as the laser beam (which is light energy) converts into heat. Plus, they offer enough cooling to minimize any damage caused to surrounding skin, reducing the risk of hyperpigmentation.

Certain pain-reducing methods, like suctions and contact cooling, are often built into the lasers. There is a new laser by Lumenis called Splendor that is very effective and significantly more comfortable than other existing lasers, and I have had great success with it, says Kim. Because this laser is much more comfortable, I have been able to treat almost all patients without any topical numbing cream which significantly reduces the waiting time for the patients as well.

Since laser hair removal heats up your skin as it blasts your hair follicles, it's important to cool it back down afterward to avoid side effects like redness. We often give people cold gauze in Ziploc bags, says Marmur. If you're getting in a car, put on the air conditioning and stay in a cool place for a bit, or take a cool shower afterward.

Marmur sends her patients home with a cooling serum, the Marmur Metamorphosis MMRevive Serum. You could also try Avne Cicalfate Restorative Protective Cream, which soothes with a combination of barrier-repairing ingredients and probiotics.

Avoiding sun exposure and wearing sunscreen is also a must, as sunlight can kick-start hyperpigmentation. Kim recommends wearing a minimum of SPF 30. Got another session coming up? Patients should not wax, pluck, or thread the treated areas in between treatments, because it's essential for the hair follicles to be intact in order for the treatments to be effective at the next session," he says.

If we're being technical, laser hair removal is something of a misnomer. It's more like laser hair reduction, says Marmur. That's because you have two types of hair: vellus hairs, which are fine baby hairs, and terminal hairs, which are more coarse. The vellus baby hairs get affected by hormones and convert to terminal hairs throughout your life, she says.

So you may do laser hair removal at 18, but by 30, you might have new growth coming in. It's just nature doing its thing. That being said, once a hair follicle root is dead, it's dead forever.

Always make sure you're going to a board-certified dermatologist or reputable practitionerthis isn't a procedure you want to cut corners on just because you found a good discount online. And don't be afraid to ask for a consultation ahead of an appointment to discuss the procedure. As for during your appointment, you'll want to make sure both you and your practitioner have safety goggles on while the laser is in process.

At-home laser hair removal devices also exist, but they're generally less effective (meaning it will take much longer to see results), and theres more room for error as the beam is less specific. This is why experts generally suggest going in-office for the procedure.

Laser hair removal costs an average of $285 for one session, according to the latest stats from the American Society of Plastic Surgeons, but some treatments can run up to $1,500 per session. That's because the cost varies widely according to a number of factors, such as the size of the area you're treating, the provider's expertise, and where you're located. Just remember: Any treatment that seems too affordable to be true often is.

Read more:
Is Laser Hair Removal Worth the Cost and Hassle? What to Know - Glamour

Recommendation and review posted by Bethany Smith

Overview:

Breast implants are artificial prosthesis used for enhancement of breast muscles for a cosmetic reason. Breast augmentation or breast reconstruction refers to the aesthetic treatment of the breast to look more youthful and appealing. There are a wide range of breast implants used in performing aesthetic procedures including those used to treat deformities, injuries, or damages.

Request For Report [emailprotected]https://www.trendsmarketresearch.com/report/sample/9848

Breast reconstruction requires tissue expanders, which help in the expansion of breast muscles and skin, followed by the permanent insertion of a breast implant after the removal of the tissue expander. These procedures improve symmetry after mastectomy and have an aesthetic appearance. The US is the major revenue contributor to this market. However, the lack of reimbursement issues may restrict the market growth. The vendors in this market are striving to address the issues by conducting evidence-based studies regarding the efficacy of breast augmentation or reconstruction.

Market Analysis:

The global breast implants market is expected to witness a CAGR of 5.89% during the forecast period 20172023. The global breast implants market size is analyzed based on three segments product type, end-users, and regions.

Factors, such as increase in beauty consciousness, growing awareness about reconstructive breast surgeries, favorable demographics across the globe, increasing aging population, are expected to drive the market growth during the forecast period. The market is witnessing emerging trends, such as an increase in the demand of composite breast implant treatments, a rise in medical tourism, and an increase in the disposable income, which will drive the market at a significant pace during the forecast period.

Regional Analysis:

The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). The Americas is the leading region for the breast implants market growth followed by Europe. Asia Pacific and ROW are set to be the emerging regions. Brazil is the most attractive market in Latin America, the popularity and the usage of breast implants are expected to rise significantly in the coming years.

Get Complete TOC with Tables and [emailprotected]https://www.trendsmarketresearch.com/report/discount/9848

Product Analysis:

Silicone and saline breast implants are the most popular among breast augmentation and reconstruction procedures and the most common surgical aesthetic procedures among end-users. Silicone breast implants dominated the market with a revenue of $1 billion in 2016 and is expected to grow at a CAGR of 6% during the forecast period. The saline breast implants segment is growing at a slow rate and is far behind the silicone breast implants segment in terms of market growth. This is due to their low adoption rate and few other complications. In 2016, there were about 64,674 saline surgical breast implants, and these implants are more prone to rippling as they have less firmness.

On an average, women have started spending $300-500 billion a year on beauty products. Moreover, advances in technology, such as use of microspheres in lightweight breast implants and the use of stem cells, are gaining popularity as a safe and simple method of breast augmentation. Furthermore, the market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the global breast implants market.

The major products in the market include:

Key Players:

The market is fragmented with many players but dominated by the top 5 players. Allergan, Mentor Worldwide, GC Aesthetics, and Sientra hold more than 85% of the market share in the total global breast implants market.

Pure play players:

POLYTECH Health & Aesthetics GmbH, GROUPE SEBBIN SAS, Establishment Labs S.A., HansBiomed Co. Ltd, CEREPLAS, LABORATOIRES ARION, Ideal Implant, Guangzhou Wanhe Plastic Materials Co., Ltd., Silimed, G&G Biotechnology Ltd, Shanghai Kangning Medical Supplies Ltd, and Implantech Associates Inc.

<<< Get COVID-19 Report Analysis >>>https://www.trendsmarketresearch.com/report/covid-19-analysis/9848

Competitive Analysis:

The global breast implants market is fragmented and has immense growth opportunities for the vendors, especially in the developed regions. The presence of large, small, and local vendors in the market creates high competition. The market is dominated by Allergan, Mentor Worldwide, GC Aesthetics, and Sientra. These vendors are consolidating their position in the market by acquiring smaller companies, expanding their business operations by leveraging their product portfolio across the globe. The competitive environment in the market will intensify further with an increase in product/service extensions, product innovations, and M&A. They form strategic alliances for marketing and manufacturing of breast implants.

Benefits:

The report provides complete details about the usage and adoption rate of breast implants for breast augmentation or reconstruction. This helps the key stakeholders to know about the major trends, drivers, investments, vertical players initiatives, and adoption rate in the upcoming years along with the details of pure play companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about key business opportunities to key stakeholders to expand their business, improve their revenue, and to analyze the market before investing or expanding the business in this market.

Originally posted here:
Breast Implants Market Growth Opportunities Created by Covid19 Outbreak - Cole of Duty

Recommendation and review posted by Bethany Smith

ZUG, Switzerland and CAMBRIDGE, Mass., June 29, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is commencing an underwritten public offering of $325,000,000 of common shares. In addition, the underwriters will have a 30-day option to purchase up to an additional $48,750,000 of common shares at the public offering price less the underwriting discount.

Goldman Sachs & Co. LLC, BofA Securities and Jefferies are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

The common shares will be offered and sold pursuant to the Companys previously filed automatically effective shelf registration statement on FormS-3(FileNo.333-227427)filed with the U.S. Securities and Exchange Commission (the SEC) on September19, 2018. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. A copy of the prospectus supplement relating to the offering will be filed with the SEC and may be obtained, when available, from Goldman Sachs & Co. LLC by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; from BofA Securities by mail at NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or from Jefferies, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at prospectus_department@jefferies.com.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding CRISPR Therapeutics anticipated public offering. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as the intended offering terms, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled Risk Factors in CRISPR Therapeutics Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on February 12, 2020, the prospectus supplement related to the public offering and other filings that CRISPR Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent CRISPR Therapeutics views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. CRISPR Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR+1 617-337-4167reides@wcgworld.com

The rest is here:
CRISPR Therapeutics Announces Proposed Offering of Common Shares - GlobeNewswire

Recommendation and review posted by Bethany Smith

In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness.

Researchers at U.S.-based Editas Medicine and Ireland-based Allergan have administered CRISPR for the first time to a person with a genetic disease. This landmark treatment uses the CRISPR approach to a specific mutation in a gene linked to childhood blindness. The mutation affects the functioning of the light-sensing compartment of the eye, called the retina, and leads to loss of the light-sensing cells.

According to the World Health Organization, at least 2.2 billion people in the world have some form of visual impairment. In the United States, approximately 200,000 people suffer from inherited forms of retinal disease for which there is no cure. But things have started to change for good. We can now see light at the end of the tunnel.

I am an ophthalmology and visual sciences researcher, and am particularly interested in these advances because my laboratory is focusing on designing new and improved gene therapy approaches to treat inherited forms of blindness.

Gene therapy involves inserting the correct copy of a gene into cells that have a mistake in the genetic sequence of that gene, recovering the normal function of the protein in the cell. The eye is an ideal organ for testing new therapeutic approaches, including CRISPR. That is because the eye is the most exposed part of our brain and thus is easily accessible.

The second reason is that retinal tissue in the eye is shielded from the bodys defense mechanism, which would otherwise consider the injected material used in gene therapy as foreign and mount a defensive attack response. Such a response would destroy the benefits associated with the treatment.

In recent years, breakthrough gene therapy studies paved the way to the first ever Food and Drug Administration-approved gene therapy drug, Luxturna TM, for a devastating childhood blindness disease, Leber congenital amaurosis Type 2.

This form of Leber congenital amaurosis is caused by mutations in a gene that codes for a protein called RPE65. The protein participates in chemical reactions that are needed to detect light. The mutations lessen or eliminate the function of RPE65, which leads to our inability to detect light blindness.

The treatment method developed simultaneously by groups at University of Pennsylvania and at University College London and Moorefields Eye Hospital involved inserting a healthy copy of the mutated gene directly into the space between the retina and the retinal pigmented epithelium, the tissue located behind the retina where the chemical reactions takes place. This gene helped the retinal pigmented epithelium cell produce the missing protein that is dysfunctional in patients.

Although the treated eyes showed vision improvement, as measured by the patients ability to navigate an obstacle course at differing light levels, it is not a permanent fix. This is due to the lack of technologies that can fix the mutated genetic code in the DNA of the cells of the patient.

Lately, scientists have been developing a powerful new tool that is shifting biology and genetic engineering into the next phase. This breakthrough gene editing technology, which is called CRISPR, enables researchers to directly edit the genetic code of cells in the eye and correct the mutation causing the disease.

Children suffering from the disease Leber congenital amaurosis Type 10 endure progressive vision loss beginning as early as one year old. This specific form of Leber congenital amaurosis is caused by a change to the DNA that affects the ability of the gene called CEP290 to make the complete protein. The loss of the CEP290 protein affects the survival and function of our light-sensing cells, called photoreceptors.

One treatment strategy is to deliver the full form of the CEP290 gene using a virus as the delivery vehicle. But the CEP290 gene is too big to be cargo for viruses. So another approach was needed. One strategy was to fix the mutation by using CRISPR.

The scientists at Editas Medicine first showed safety and proof of the concept of the CRISPR strategy in cells extracted from patient skin biopsy and in nonhuman primate animals.

These studies led to the formulation of the first ever in human CRISPR gene therapeutic clinical trial. This Phase 1 and Phase 2 trial will eventually assess the safety and efficacy of the CRISPR therapy in 18 Leber congenital amaurosis Type 10 patients. The patients receive a dose of the therapy while under anesthesia when the retina surgeon uses a scope, needle and syringe to inject the CRISPR enzyme and nucleic acids into the back of the eye near the photoreceptors.

To make sure that the experiment is working and safe for the patients, the clinical trial has recruited people with late-stage disease and no hope of recovering their vision. The doctors are also injecting the CRISPR editing tools into only one eye.

An ongoing project in my laboratory focuses on designing a gene therapy approach for the same gene CEP290. Contrary to the CRISPR approach, which can target only a specific mutation at one time, my team is developing an approach that would work for all CEP290 mutations in Leber congenital amaurosis Type 10.

This approach involves using shorter yet functional forms of the CEP290 protein that can be delivered to the photoreceptors using the viruses approved for clinical use.

Gene therapy that involves CRISPR promises a permanent fix and a significantly reduced recovery period. A downside of the CRISPR approach is the possibility of an off-target effect in which another region of the cells DNA is edited, which could cause undesirable side effects, such as cancer. However, new and improved strategies have made such likelihood very low.

Although the CRISPR study is for a specific mutation in CEP290, I believe the use of CRISPR technology in the body to be exciting and a giant leap. I know this treatment is in an early phase, but it shows clear promise. In my mind, as well as the minds of many other scientists, CRISPR-mediated therapeutic innovation absolutely holds immense promise.

In another study just reported in the journal Science, German and Swiss scientists have developed a revolutionary technology, which enables mice and human retinas to detect infrared radiation. This ability could be useful for patients suffering from loss of photoreceptors and sight.

The researchers demonstrated this approach, inspired by the ability of snakes and bats to see heat, by endowing mice and postmortem human retinas with a protein that becomes active in response to heat. Infrared light is light emitted by warm objects that is beyond the visible spectrum.

The heat warms a specially engineered gold particle that the researchers introduced into the retina. This particle binds to the protein and helps it convert the heat signal into electrical signals that are then sent to the brain.

In the future, more research is needed to tweak the ability of the infrared sensitive proteins to different wave lengths of light that will also enhance the remaining vision.

This approach is still being tested in animals and in retinal tissue in the lab. But all approaches suggest that it might be possible to either restore, enhance or provide patients with forms of vision used by other species.

[Get our best science, health and technology stories. Sign up for The Conversations science newsletter.]

Read the original:
Gene therapy and CRISPR strategies for curing blindness (Yes, you read that right) - The Conversation US

Recommendation and review posted by Bethany Smith

Text size

The biotech firm CRISPR Therapeutics is one of Piper Sandler analyst Ted Tenthoffs top picks for 2020, he reaffirmed in a note out Monday.

CRISPR Therapeutics stock (ticker: CRSP) was up 0.5% Monday morning after rising as much as 3.9% in pre-market trading. Shares fell 2.6% on Friday. CRISPR Therapeutics, which is developing therapeutic genome-editing technology, announced last Thursday that it would build a new manufacturing facility in Massachusetts to produce its experimental cell therapies.

In his Monday note, Tenthoff wrote that the company is moving forward with its CRISPR-based allogenic CAR-T cell therapies, a set of experimental cancer treatments, with data expected by the end of the year.

CRISPR [Therapeutics] remains a top pick for 2020, Tenthoff wrote. He maintained his Overweight rating on this stock, and his $104 price target. The stock closed at $74.04 on Friday and traded as high as $76.98 in pre-market trading Monday. CRISPR Therapeutics stock was recently trading up 2.25% to $75.71.

Shares of CRISPR Therapeutics are up about 22% so far this year. Of the 17 analysts tracked by FactSet who cover the stock, 11 assign it a Buy rating. The analysts have a mean target price of $75.75.

In his note on Monday, Tenthoff highlighted recent data showing promising early results in two transfusion-dependent beta-thalassemia patients who had received CTX001, a treatment CRISPR Therapeutics is developing in partnership with Vertex Pharmaceuticals (VRTX).

He also highlighted developments in the companys CAR-T cancer programs, a handful of which are beginning or about to begin Phase I/II studies. We see the potential for CRISPR to garner significant value from its wholly-owned CAR-T pipeline, Tenthoff wrote.

CRISPR Therapeutics has a market capitalization of $4.5 billion. It has outperformed the iShares Nasdaq Biotechnology ETF (IBB) so far this year, which is up 11.4%, and the S&P 500, which is down 6.9%.

Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com

Excerpt from:
CRISPR Therapeutics Is a Top Pick for Piper Sandler. Heres Why. - Barron's

Recommendation and review posted by Bethany Smith

What happened

CRISPR Therapeutics (NASDAQ:CRSP) stock is hot this week, after the biotech presented four research posters at the American Association for Cancer Research's Virtual Meeting II this week, offering preclinical data on its gene-editing cancer research and sparking a flurry of supportive notes from Wall Street.

CRISPR stock is up a solid 4.5% as of 2:55 p.m. EDT today and, added to yesterday's gains, has risen more than 9% over the past two days.

Image source: Getty Images.

CRISPR's CAR T-cell technology modifies a patient's immune system T cells and tailors them to fight specific forms of cancer. In this week's posters, the company is said to be reporting data showing that its CTX130 treatment is both specific and potent in fighting both hematologic and solid tumors.

Specific news on the findings is hard to come by, but whatever CRISPR is saying, analysts seem to like it -- a lot. In less than just the last 24 hours, no fewer than three separate Wall Street firms have raised or reiterated their price targets on CRISPR stock. TheFly.com is reporting that Oppenheimer & Co. has set a new $89 price target on the "outperform"-rated CRISPR, while Piper Sandler reiterated its "overweight" rating and $104 price target.

StreetInsider.com adds that Stifel Nicolaus, too, is optimistic, and has raised its price target to $61.

That last rating isn't quite as bullish as the first two. After their two-day run-up, CRISPR shares already sell for more than $75, after all -- and accordingly, Stifel only gives the stock a "hold" rating. Still, investors seem to think that two out of three isn't bad, and are focusing on the more positive valuation estimates from Oppenheimer and Piper Sandler today.

Speaking of valuation, investors looking at CRISPR for the first time in light of these analyst endorsements may be encouraged to see that this start-up biotech already seems to be profitable and free-cash-flow positive -- but don't be fooled. CRISPR's flush with cash currently because it just received a big milestone payment from partner Vertex Pharmaceuticals. Analysts expect the company will end this year with a loss, however, and will continue losing money for at least the next three years before becoming profitable again.

Investing in CRISPR still requires keeping an eye on the big picture, and monitoring the company's steady progress toward long-term, sustained sales, revenue, and profits -- all of which are years in the future. In the near term, the company's numbers are bound to resume looking pretty ugly, and sooner rather than later.

Read the original:
Why CRISPR Therapeutics Stock Just Popped Another 5% - Motley Fool

Recommendation and review posted by Bethany Smith

The first patient to be treated for Sickle Cell Disease with the revolutionary gene-editing program CRISPER had a transfusion of billions of modified cells last year, and now a year later her treatment is still working perfectly.

Before Victoria Gray underwent the treatment in mid-2019 she had been experiencing frequent bouts of physical pain. Patients like her are often forced to get blood transfusionsan average of seven per year in Grays casein order to ensure that their body has enough healthy red blood cells to carry oxygen throughout the body.

But now, alleviation of almost all of her symptoms has allowed her to stay out of Mississippi hospitals and support her three kids while her husband, a national guardsman, was temporarily deployed out of town.

The era of COVID-19 is hardly the time to be popping into a hospital for a blood transfusion, so the improvement for Gray has been substantialand feels like a miracle.

Since my treatment Ive been able to do everything for myself, everything for my kids, she told NPR. And its been a joy not only for me but for the people around me.

RELATED: Worlds Second Person Cured of HIV: 40-Year-old Man is Confirmed to Be 30 Months Virus-Free

An artifact of the strange genetic history of humanity, sickle-cell genes evolved in Africans as a strong defense against malaria, but they can also increase the chance of dying relatively young from the blood disorder.

However, her case, along with those of two others who were treated in the same way, is producing only good news a year later. Dr. Haydar Frangoul of the Sarah Cannon Research Institute in Nashville, Tennessee, who is treating Gray, described it as extremely thrilling to see and extremely exciting.

Frangoul and other scientists using CRISPER presented the results of their latest testing of the three cases to the European Hematology Association on June 12th. The two other subjects had a related condition, beta thalassemia, and were treated in Germany with a similar method and have now been able to live without blood transfusions for 15 months.

RELATED: After Her Years of Research, a Cambridge Scientist Could Be on the Verge of Curing Multiple Sclerosis

I think this is a huge leap for the medical field, Frangoul told NPR in an interview, asserting that Gray will be, hopefully, the first of many thousands more of patients who will be able to see things they never imagined possible.

High school graduations, college graduations, weddings, grandkids I thought I wouldnt see none of that, Gray said.

SHARE the Good News on Social Media (Photo by Libertas Academica, CC license on Foter)

The rest is here:
First Sickle Cell Patient Treated with CRISPR Gene Editing is Now Thriving One Year Later, And Able to Care For Her Kids - Good News Network

Recommendation and review posted by Bethany Smith

Latest Report on CRISPR and Cas Genes Market Size | Industry Segment by Applications (Genome Engineering, Disease Models and Others), by Type (Vector-based Cas and DNA-free Cas), Regional Outlook, Market Demand, Latest Trends, CRISPR and Cas Genes Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.

The research report on CRISPR and Cas Genes market provides a broad perspective of this business vertical and comprises of substantial details such as market size, revenue estimation, industry remuneration, and market valuation over the study period.

The study assesses the key factors positively impacting the overall industry landscape on the basis of market growth and sales acceleration. Moreover, it delivers information regarding the major market trends and their impact on the business space.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/230125

Major parameters of CRISPR and Cas Genes market report:

Regional study of CRISPR and Cas Genes market:

CRISPR and Cas Genes Market Segmentation: Americas, APAC, Europe, Middle East & Africa.

An overview of the geographical landscape of CRISPR and Cas Genes market:

Product spectrum and application scope of CRISPR and Cas Genes market:

Product landscape:

Product types: Vector-based Cas and DNA-free Cas

Key factors encompassed in the report:

Application Landscape:

Application segmentation: Genome Engineering, Disease Models and Others

Data delivered by the study:

Other details specified in the report:

Competitive space of the CRISPR and Cas Genes market:

Leading players in the CRISPR and Cas Genes market: Synthego, Horizon Discovery Group Co., Thermo Fisher Scientific, Inc., Addgene, Merck, GenScript, OriGene Technologies, Inc., Integrated DNA Technologies, Inc., New England Biolabs, Transposagen Biopharmaceuticals, Inc., Cellecta, Inc., Applied StemCell, Inc. and Agilent Technologies

Key aspects listed in the report:

Key questions answered in this report:

What will the market size be in 2025 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/230125

Visit link:
CRISPR and Cas Genes Market with Future Prospects, Key Player SWOT Analysis and - News by aeresearch

Recommendation and review posted by Bethany Smith

Some stocks have just one problem: Once you've bought them, you never want to sell them.That's the case with Vertex Pharmaceuticals (NASDAQ:VRTX), a biotech company with a leading position in the area of cystic fibrosis.

Vertex's shares have climbed 35% this year to trade near a record high. As the coronavirus outbreak has weighed on business across industries, the impact on this company has been limited to slowdowns in certain clinical trials. Vertex actually revised its cystic fibrosis revenue estimate for the year -- upward.

Image source: Getty Images.

Beyond this winning performance, here are three reasons to grab Vertex now and hang on for the long term.

Vertex was already a leader in cystic fibrosis with three marketed products when a fourth, Trikafta, was approved in October 2019. In the third quarter of 2019, just before Trikafta's launch, the company's cystic fibrosis drugs generated a combined $950 million, a 21% increase from the year-earlier period. Trikafta immediately leaped ahead. In its first full quarter on the market, the drug's $895 million in sales represented 60% of product revenue. In Vertex's most recent earnings call, the company predicted that Trikafta will drive revenue growth in the coming years.

What makes Trikafta such a winning product? This combination therapy, which includes elexacaftor, tezacaftor, and ivacaftor, may treat up to 90% of cystic fibrosis patients worldwide, Vertex says. Trikafta addresses the underlying cause of the disease in patients with the most common genetic mutation.

Trikafta is clearly a blockbuster in the making. Along with Vertex's other cystic fibrosis drugs, it's creating a long-term growth story. Vertex's cystic fibrosis treatments may generate more than $10 billion in sales by 2028, according to Morningstar. That's compared to $4 billion last year.

Gene and cell therapies involve introducing genetic material or living cells into the body to produce a therapeutic effect. Last year, Vertex took steps to solidify its presence in this promising area. The company announced a research center dedicated to the program, acquired gene-editing specialist Exonics Therapeutics, and expanded its partnership with CRISPR Therapeutics (NASDAQ:CRSP).

Using expertise from Exonics and CRISPR, Vertex is boosting its gene-editing program for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. In gene editing, DNA is changed -- or literally "edited" -- in order to treat disease. It's wise of Vertex to pursue this therapeutic technique now. At a 25% compound annual growth rate, the global gene-editing market is expected to reach $4.4 billion by 2023, according to BCC Research. Grand View Research forecasts that the market will hit $8 billion by 2025.

Most recently, Vertex and CRISPR announced encouraging results from phase 1/2 clinical trials of the CTX001 gene-editing therapy in two blood disorders: transfusion-dependent beta-thalassemia and severe sickle cell disease. Early patients were transfusion-independent months after treatment, and the data demonstrated clinical proof of concept. The companies will provide more data later this year.

Vertex's annual revenue has increased steadily since 2015. As for earnings, they have soared past analysts' estimates in the past four quarters. For instance, in the most recent quarter, earnings per share came in at $2.56 compared with the average forecast of $1.84.

History isn't always indicative of the future. One small issue facing Vertex is that its up-and-coming therapies are all in phase 2 studies, or in earlier review stages. So we can't expect new drug approvals in the near term.

That said, Vertex's cystic fibrosis platform is strong enough to power the company along until earlier-stage programs bear fruit. Considering Vertex's recent approval of Trikafta, and the drug's hugely successful debut, it's reasonable to expect revenue to climb moving forward.

Vertex is trading at 51 times trailing-12-month earnings, and the shares have surpassed Wall Street's average price target by about 3%. By comparison, other profitable biotech companies like Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) trade at just under 20 times earnings. So, Vertex isn't cheap. Still, for the three reasons above, I think this biotech stockhas plenty of room to move higher over the long term.

Continue reading here:
3 Reasons Why Vertex Is a Great Stock to Buy and Hold for the Long Term - Motley Fool

Recommendation and review posted by Bethany Smith

The market research report published by QYResearch is a brilliant, in-depth, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Withania Somnifera Extract market. It informs readers about key trends and opportunities in the global Withania Somnifera Extract market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Withania Somnifera Extract market.

Key companies operating in the global Withania Somnifera Extract market include , Life Extension, Taos Herb Company, General Nutrition Centers, Jarrow Formulas, Huge Mountain, Organic India, The Vitamin Shoppe, NOW Foods, Solgar, Piping Rock, Swanson

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1525669/global-withania-somnifera-extract-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Withania Somnifera Extract market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Withania Somnifera Extract Market Segment By Type:

, Capsule, Liquid

Global Withania Somnifera Extract Market Segment By Application:

, Health Products, Drug

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Withania Somnifera Extract market.

Key companies operating in the global Withania Somnifera Extract market include , Life Extension, Taos Herb Company, General Nutrition Centers, Jarrow Formulas, Huge Mountain, Organic India, The Vitamin Shoppe, NOW Foods, Solgar, Piping Rock, Swanson

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1525669/global-withania-somnifera-extract-market

TOC

1 Withania Somnifera Extract Market Overview1.1 Product Overview and Scope of Withania Somnifera Extract1.2 Withania Somnifera Extract Segment by Type1.2.1 Global Withania Somnifera Extract Sales Growth Rate Comparison by Type (2021-2026)1.2.2 Capsule1.2.3 Liquid1.3 Withania Somnifera Extract Segment by Application1.3.1 Withania Somnifera Extract Sales Comparison by Application: 2020 VS 20261.3.2 Health Products1.3.3 Drug1.4 Global Withania Somnifera Extract Market Size Estimates and Forecasts1.4.1 Global Withania Somnifera Extract Revenue 2015-20261.4.2 Global Withania Somnifera Extract Sales 2015-20261.4.3 Withania Somnifera Extract Market Size by Region: 2020 Versus 2026 2 Global Withania Somnifera Extract Market Competition by Manufacturers2.1 Global Withania Somnifera Extract Sales Market Share by Manufacturers (2015-2020)2.2 Global Withania Somnifera Extract Revenue Share by Manufacturers (2015-2020)2.3 Global Withania Somnifera Extract Average Price by Manufacturers (2015-2020)2.4 Manufacturers Withania Somnifera Extract Manufacturing Sites, Area Served, Product Type2.5 Withania Somnifera Extract Market Competitive Situation and Trends2.5.1 Withania Somnifera Extract Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key Withania Somnifera Extract Players (Opinion Leaders) 3 Withania Somnifera Extract Retrospective Market Scenario by Region3.1 Global Withania Somnifera Extract Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global Withania Somnifera Extract Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America Withania Somnifera Extract Market Facts & Figures by Country3.3.1 North America Withania Somnifera Extract Sales by Country3.3.2 North America Withania Somnifera Extract Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe Withania Somnifera Extract Market Facts & Figures by Country3.4.1 Europe Withania Somnifera Extract Sales by Country3.4.2 Europe Withania Somnifera Extract Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific Withania Somnifera Extract Market Facts & Figures by Region3.5.1 Asia Pacific Withania Somnifera Extract Sales by Region3.5.2 Asia Pacific Withania Somnifera Extract Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America Withania Somnifera Extract Market Facts & Figures by Country3.6.1 Latin America Withania Somnifera Extract Sales by Country3.6.2 Latin America Withania Somnifera Extract Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa Withania Somnifera Extract Market Facts & Figures by Country3.7.1 Middle East and Africa Withania Somnifera Extract Sales by Country3.7.2 Middle East and Africa Withania Somnifera Extract Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global Withania Somnifera Extract Historic Market Analysis by Type4.1 Global Withania Somnifera Extract Sales Market Share by Type (2015-2020)4.2 Global Withania Somnifera Extract Revenue Market Share by Type (2015-2020)4.3 Global Withania Somnifera Extract Price Market Share by Type (2015-2020)4.4 Global Withania Somnifera Extract Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Withania Somnifera Extract Historic Market Analysis by Application5.1 Global Withania Somnifera Extract Sales Market Share by Application (2015-2020)5.2 Global Withania Somnifera Extract Revenue Market Share by Application (2015-2020)5.3 Global Withania Somnifera Extract Price by Application (2015-2020) 6 Company Profiles and Key Figures in Withania Somnifera Extract Business6.1 Life Extension6.1.1 Corporation Information6.1.2 Life Extension Description, Business Overview and Total Revenue6.1.3 Life Extension Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.1.4 Life Extension Products Offered6.1.5 Life Extension Recent Development6.2 Taos Herb Company6.2.1 Taos Herb Company Withania Somnifera Extract Production Sites and Area Served6.2.2 Taos Herb Company Description, Business Overview and Total Revenue6.2.3 Taos Herb Company Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.2.4 Taos Herb Company Products Offered6.2.5 Taos Herb Company Recent Development6.3 General Nutrition Centers6.3.1 General Nutrition Centers Withania Somnifera Extract Production Sites and Area Served6.3.2 General Nutrition Centers Description, Business Overview and Total Revenue6.3.3 General Nutrition Centers Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.3.4 General Nutrition Centers Products Offered6.3.5 General Nutrition Centers Recent Development6.4 Jarrow Formulas6.4.1 Jarrow Formulas Withania Somnifera Extract Production Sites and Area Served6.4.2 Jarrow Formulas Description, Business Overview and Total Revenue6.4.3 Jarrow Formulas Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.4.4 Jarrow Formulas Products Offered6.4.5 Jarrow Formulas Recent Development6.5 Huge Mountain6.5.1 Huge Mountain Withania Somnifera Extract Production Sites and Area Served6.5.2 Huge Mountain Description, Business Overview and Total Revenue6.5.3 Huge Mountain Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.5.4 Huge Mountain Products Offered6.5.5 Huge Mountain Recent Development6.6 Organic India6.6.1 Organic India Withania Somnifera Extract Production Sites and Area Served6.6.2 Organic India Description, Business Overview and Total Revenue6.6.3 Organic India Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.6.4 Organic India Products Offered6.6.5 Organic India Recent Development6.7 The Vitamin Shoppe6.6.1 The Vitamin Shoppe Withania Somnifera Extract Production Sites and Area Served6.6.2 The Vitamin Shoppe Description, Business Overview and Total Revenue6.6.3 The Vitamin Shoppe Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.4.4 The Vitamin Shoppe Products Offered6.7.5 The Vitamin Shoppe Recent Development6.8 NOW Foods6.8.1 NOW Foods Withania Somnifera Extract Production Sites and Area Served6.8.2 NOW Foods Description, Business Overview and Total Revenue6.8.3 NOW Foods Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.8.4 NOW Foods Products Offered6.8.5 NOW Foods Recent Development6.9 Solgar6.9.1 Solgar Withania Somnifera Extract Production Sites and Area Served6.9.2 Solgar Description, Business Overview and Total Revenue6.9.3 Solgar Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.9.4 Solgar Products Offered6.9.5 Solgar Recent Development6.10 Piping Rock6.10.1 Piping Rock Withania Somnifera Extract Production Sites and Area Served6.10.2 Piping Rock Description, Business Overview and Total Revenue6.10.3 Piping Rock Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.10.4 Piping Rock Products Offered6.10.5 Piping Rock Recent Development6.11 Swanson6.11.1 Swanson Withania Somnifera Extract Production Sites and Area Served6.11.2 Swanson Withania Somnifera Extract Description, Business Overview and Total Revenue6.11.3 Swanson Withania Somnifera Extract Sales, Revenue and Gross Margin (2015-2020)6.11.4 Swanson Products Offered6.11.5 Swanson Recent Development 7 Withania Somnifera Extract Manufacturing Cost Analysis7.1 Withania Somnifera Extract Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of Withania Somnifera Extract7.4 Withania Somnifera Extract Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 Withania Somnifera Extract Distributors List8.3 Withania Somnifera Extract Customers 9 Market Dynamics9.1 Market Trends9.2 Opportunities and Drivers9.3 Challenges9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global Withania Somnifera Extract Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of Withania Somnifera Extract by Type (2021-2026)10.1.2 Global Forecasted Revenue of Withania Somnifera Extract by Type (2021-2026)10.2 Withania Somnifera Extract Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of Withania Somnifera Extract by Application (2021-2026)10.2.2 Global Forecasted Revenue of Withania Somnifera Extract by Application (2021-2026)10.3 Withania Somnifera Extract Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of Withania Somnifera Extract by Region (2021-2026)10.3.2 Global Forecasted Revenue of Withania Somnifera Extract by Region (2021-2026)10.4 North America Withania Somnifera Extract Estimates and Projections (2021-2026)10.5 Europe Withania Somnifera Extract Estimates and Projections (2021-2026)10.6 Asia Pacific Withania Somnifera Extract Estimates and Projections (2021-2026)10.7 Latin America Withania Somnifera Extract Estimates and Projections (2021-2026)10.8 Middle East and Africa Withania Somnifera Extract Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source12.1 Methodology/Research Approach12.1.1 Research Programs/Design12.1.2 Market Size Estimation12.1.3 Market Breakdown and Data Triangulation12.2 Data Source12.2.1 Secondary Sources12.2.2 Primary Sources12.3 Author List12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Visit link:
Trending: Withania Somnifera Extract Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026|...

Recommendation and review posted by Bethany Smith

High pressure processing (HPP) is non-thermal food preservation and sterilization technique, which has been developed to avoid chemical and thermal preservation of food. High pressure processing is also known as Pascalization or bridgmanization or high hydrostatic pressure (HHP), or ultra-high pressure (UHP). It is a natural and environmental friendly process that doesnt alter foods original properties such as flavor, color or texture. It is proved as a successful and safe alternative for traditional chemical and thermal preservation techniques.

From 1990s HPP technique is popularly being used in Japan and other part of Asia. Initially it was being used only for preservation of juices, jellies and jams. But considering market demand for naturally preserved foods and benefits of HPP, the technique is now popular for preservation of almost all the food products such as salads, fish and meat, seafood, yogurts, rice cakes, grains etc.

Increasing market demand for naturally preserved food is market driver for high pressure processing food technique. When HPP is used for rice and grains processing, the allergen protein releases from rice grains and makes rice allergen free.

High Pressure Processing (HPP) For Rice & Grain Market Segmentation

High pressure processing market can be segmented on the basis of processing equipment type such as semi-continues equipment, and batch processing equipment. Bach processing is mainly used for pre-packaged food and semi-continuous process is used for foods in pumpable liquid form. In rice and grains processing semi-continuous process is used popularly.

High pressure processing (HPP) market is later segmented on the basis of production scale as small scale, mid-scale and large scale production. Large scale production is normally used in developed markets, where as mid-scale and small scale are getting popular in developing markets. High pressure processing market is further segmented on the basis of region as, Latin America, North America, Asia Pacific Excluding Japan, Japan, Europe, Middle East and Africa.

High Pressure Processing (HPP) For Rice & Grain Global Market Drivers & Trends

Rising natural and safe food demand from rapidly growing global population is major factor driving market demand for HPP for rice & grains. As HPP breaks down the allergic protein content of rice and grains and makes it safe for consumption, food processing industries are concentrating on High pressure processing of rice and grains.

Download Sample [emailprotected]https://www.futuremarketinsights.com/reports/sample/rep-gb-1880

Not only the allergens removal properties, but other preservation advantages such as shelf life extension, greater quality, destroyed pathogens etc. are other factors attracting producers and fueling market demand for HPP technique for rice and grains.

Moreover to meet the safe and natural food demands of the 21st century consumer,the global food industry is rapidly moving toward product innovative and new product development through new processing methods. HPP for rice and grains is one of them, gaining significant market demand.

In regional outlook of high pressure processing for rice and grain market, Japan and Asia Pacific Excluding Japan are major players in HPP for rice and grain market, as being major producer and consumers of rice and grains. As U.S. FDA has accepted commercial use of HPP for low acid foods like grains and rice, North America is considered as another major market as well as with increasing consumer demand for non-synthetic natural food preservation methods, Europe has also adapted HPP techniques for rice and grain, and for many other food products such as juices, bakery products, jams, jellies etc. In Europe and North America markets, HPP is widely used for juices and beverages processing.

However Middle East and Africa markets are still in their nascent stage of development in HPP for rice and grains.

High Pressure Processing (HPP) For Rice & Grain Market Key Players:

All rice and grain producers and other food manufacturers cannot afford to purchase high cost HPP machines. And therefore to facilitate some market player providing HPP on commercial tolling basis to the food manufacturing industries, includes American Pasteurization Company, Avure HPP Food Processing, High Pressure Process Tolling Ltd., Stay Fresh Foods, Hormel Foods, Motivatit, APA Processing, Raw Pressery etc. However few major market players providing HPP machinery and technology includes Kobe steel co. ltd, Hoiperbaric S.A, Amec ,Next HPP etc.

The report covers exhaustive analysis on:

Regional analysis for High Pressure Processing (HPP) For Rice & Grain Market includes

Request For Methodology @https://www.futuremarketinsights.com/askus/rep-gb-1880

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and regions.

Report Highlights:

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

The rest is here:
High Pressure Processing (HPP) for Rice and Grain Market Estimated To Expand at a Robust CAGR by 2030 | FMI Report - Cole of Duty

Recommendation and review posted by Bethany Smith

The market intelligence report on Withania Somnifera Extract Sales market is prepared through diligent compilation of analytical study based on historical records, current and upcoming statistics and future developments. The intelligence report prepared contains details on the leading players of the Global Withania Somnifera Extract Sales Market, along with various depending aspects related and associated with the market. In addition, the report utilizes various analytical and test methods such as S.T.E.E.P.L.E., Regression analysis, S.W.O.T. (analysis methods) and ANOVA and FRAP (test methods), to identify the overlooked factor that could alter the state of the market and its implication it would have on the trend of the market.

Synopsis of Withania Somnifera Extract Sales Market Report:The report covers an analysis of the Withania Somnifera Extract Sales Market and the forecast for the same on a global and regional level, including a deep analysis of microeconomic and macroeconomic factors impacting the growth of the market. Crucial market information and data regarding newest industry data, market future trends, identification of the products and end users driving revenue growth and profitability, is made available in this report. Through an exhaustive study components such as professional and in-depth study of the current state of market, the major drivers and restraints driving the market, etc. are simplified to help you become familiar with key dynamics of the Global Withania Somnifera Extract Sales Market.

Have some queries? Get Free Sample PDF Copy based on Latest Research on Withania Somnifera Extract Sales Market after the Covid-19 impact: https://www.acquiremarketresearch.com/sample-request/367102/

The report provides a granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. Following are some of the segmentations provided in the report ;

Leading players operating in the global Withania Somnifera Extract Sales market are: Life Extension, Taos Herb Company, General Nutrition Centers, Jarrow Formulas, Huge Mountain, Organic India, The Vitamin Shoppe, NOW Foods, Solgar, Piping Rock, Swanson

Withania Somnifera Extract Sales Market Growth by Types: Capsule, Liquid

Withania Somnifera Extract Sales Market Extension by Applications: Health Products, Drug

The Global version of this report with a geographical classification would cover regions: North America (USA, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Report on Withania Somnifera Extract Sales Market (covering Covid-19 impacts) at an Impressive Discount! With Corporate Email ID @ https://www.acquiremarketresearch.com/discount-request/367102/

Key Benefits of Global Withania Somnifera Extract Sales Market Report:1.This study presents an analytical depiction of the global Withania Somnifera Extract Sales industry along with the current trends and future estimations to depict the imminent investment pockets.2.The overall Withania Somnifera Extract Sales market potential is determined to understand the lucrative trends to gain a stronger foothold in the industry.3.The report includes information related to key drivers, restraints, and opportunities with a detailed impact analysis.4.The current market is quantitatively analyzed, to highlight the financial competency of the Withania Somnifera Extract Sales market.5.To identify and state the demand and supply forecast, Porters five forces analysis illustrates the potency of the buyers and suppliers in the market.

In order to accurately measure the market integration and its competition we have included a special study of impact of Covid-19 on the Withania Somnifera Extract Sales market. Additionally, in order to help our customers avoid the pandemic, we have included the verified information related to Covid-19 in our reports.

Exponential points covered in the Withania Somnifera Extract Sales Market Report that include conditions after the impact of Covid-19;What are the regions that have seen a greater impact on their market?What are the current financial situations of the market leaders?What are the emerging opportunities that can provide higher profits?What is the condition of the suppliers market, and the raw materials market?Provided with the challenge, how have the market leaders maintained their competitive edge?

For more details on Withania Somnifera Extract Sales Market Report (Post Covid-19 impact), Ask Our Expert (Use Corporate email ID to Get Higher Priority) @ https://www.acquiremarketresearch.com/enquire-before/367102/

About us:

At Acquire Market Research the database of the company is updated on a daily basis to provide the clients with reports containing the latest trends and in-depth analysis of the industry. While each report initially generated is prepared with a set benchmark of the industry, the reports are customizable to meet the requirements of the client. After careful validation of the report by our expert analysts, the report on Withania Somnifera Extract Sales Market has been published.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

See the original post:
Withania Somnifera Extract Sales Market Short Term and Long-Term Impact of Covid-19 On The Market-2020-2024 - Owned

Recommendation and review posted by Bethany Smith

People under 28 or over 30 in Madison, Morgan, Marshall, Jackson and Limestone counties can get reduced pricing on tests.

HUNTSVILLE, Ala. The HudsonAlpha Institute for Biotechnology is offering cancer genetic risk testing to all adults in Madison, Morgan, Marshall, Jackson and Limestone counties.

The test is free for people ages 28-30 and available at a reduced cost to others.

HudsonAlpha says that they have reached capacity for the free-for-all-adults testing program.

According to HudsonAlpha, the free test offered by Kailos Genetics screens for the well-known BRCA1 and BRCA2 genes, as well as several dozen other genes linked to breast, ovarian, colon, prostate, pancreatic, and other cancers.

The testing is offered through the Information is Power initiative, established in 2015 for people interested in learning more about their cancer risk.

If you want to learn more about genetic testing for cancer risk, HudsonAlpha, the Princess Theatre, and Decatur Morgan Women's Healthcare are holding a free virtual event July 15 at noon. Cancer researcher, Sara Cooper, PhD, and genetic counselor, Veronica Greve, will discuss the latest in cancer research and genetic testing.

You're also eligible to win a free test, regardless of age, a free test, if you register to attend the virtual event on July 15.

To join the virtual event, register here.

To order a test for yourself or someone else, click here.

Read the original:
Free cancer genetic risk testing available to adults 28-30 in five counties - WZDX

Recommendation and review posted by Bethany Smith

Global Predictive Genetic Testing Market 2020-2025 is one of the most comprehensive and important additions to Adroit Market Research archive of market research studies. It offers detailed research and analysis of key aspects of the global market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Predictive Genetic Testing market. The report also analyzes factors such as drivers, restraints, opportunities, and trends affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides particulars of the competitive landscape for market leaders.

Get sample copy of Predictive Genetic Testing Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/1276

The analysis is likely to create in-depth analysis predicated on preceding questions and comprehensive research regarding the evolution setting, market dimensions, development tendency, performance status and future development tendency of Predictive Genetic Testing market on based on saying current position 2020 therefore as to create complete organization and decision on your contest situation and development tendency of global Predictive Genetic Testing market and assist brands and investment company to grasp the growth span of the market.

Top Leading Key Players are:

Agilent, Technologies, Inc., BGI Genomics, F.Hoffman-La Roche Ltd., Genes In Life., Invitae Corporation, Illumina, Inc., 23andMe, Myriad Genetics, Inc., Pathway Genomics and Thermo Fisher Scientific, Inc.

Read complete report with TOC at: https://www.adroitmarketresearch.com/industry-reports/predictive-genetic-testing-market

Predictive Genetic Testing market is split by Type and by Application. For the period 2020-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets. Predictive Genetic Testing market competitive landscape provides details by vendors, including company overview, company total revenue, market potential, global presence, sales and revenue generated, market share, price, production sites and facilities, SWOT analysis.

Predictive Genetic Testing market study further highlights the segmentation of the Predictive Genetic Testing industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Predictive Genetic Testing market report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Predictive Genetic Testing market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Predictive Genetic Testing market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1276

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

More:
Predictive Genetic Testing Market: Expected to Demand Product Scope, Market Summary, Prospects and Driving Force 2025 - Jewish Life News

Recommendation and review posted by Bethany Smith

New Jersey, United States,- The latest research study on Prenatal and New-born Genetic Testing Market Added by Verified Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Prenatal and New-born Genetic Testing market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

Global Prenatal and Newborn Genetic Testing Market was valued at USD 7.07 Billion in 2019 and is projected to reach USD 15.85 Billion by 2027, growing at a CAGR of 10.6% from 2020 to 2027.

Download Sample Copy of Prenatal and New-born Genetic Testing Market Report Study 2020-2027 @ https://www.verifiedmarketresearch.com/download-sample/?rid=38619&utm_source=COD&utm_medium=002

The research report on the Prenatal and New-born Genetic Testing market provides a granular assessment of this business vertical and includes information concerning the market tendencies such as revenue estimations, current remuneration, market valuation, and market size over the estimated timeframe.

Major Players Covered in this Report are:

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Prenatal and New-born Genetic Testing market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

The scope of the Report:

The report segments the global Prenatal and New-born Genetic Testing market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritty of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also addresses political scenarios that are expected to impact the market in both small and big ways. The report on the global Prenatal and New-born Genetic Testing market examines changing regulatory scenarios to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Discount on Prenatal and New-born Genetic Testing Market Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=38619&utm_source=COD&utm_medium=002

As per the regional scope of the Prenatal and New-born Genetic Testing market:

Highlights of the report:

Key Questions Answered in the report:

Learn More about this report @ https://www.verifiedmarketresearch.com/product/prenatal-and-newborn-genetic-testing-market/?utm_source=COD&utm_medium=002

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Hardware Security Modules Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Physical Security Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Wearable Electronics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Microgrid Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Scintillator Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Original post:
Prenatal and New-born Genetic Testing Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 - Cole of Duty

Recommendation and review posted by Bethany Smith

Learn details of the Preimplantation Genetic Testing Market: Statistics, Facts And Figures, Growth Overview, Size, Major Players, Industry Outlook And Regional Analysis, Swot Analysis And Forecast To 2029. Extensive Study on Impact of the novel coronavirus (COVID 19) pandemic on the preimplantation genetic testing market based on Current Analysis of Potential Growth Challenges and Future Developments till 2029.

The Preimplantation Genetic Testing report encompasses a careful analysis of a small and economic science issue that is influencing the expansion of the market. The Preimplantation Genetic Testing market has cardinal frameworks that embody market outlook, Preimplantation Genetic Testing current methods, institution, size, revenue and latest trends of Preimplantation Genetic Testing market from 2020-2029.The Influential Players Covered In This Report Are: Illumina, Thermo Fisher, Agilent Technologies, Perkinelmer, Coopersurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute, Good Start Genetics, Invicta Genetics, Combimatrix, Gen.

Download the PDF Sample To Understand The CORONA Virus/COVID19 Impact On Preimplantation Genetic Testing Market :https://market.us/report/preimplantation-genetic-testing-market/request-sample/

**Note:Our Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC,DetailedList of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology**

The report conjointly provides a summary of producing knowledge that includes: size, revenue(USD), statistics, development, worth and market value. The analysis for Preimplantation Genetic Testing analyzes current and future prospects to grasp the steadiness of the market. the worldwide Preimplantation Genetic Testing market have comprehensive prospect that covers the assorted facet of preimplantation genetic testing market. The Preimplantation Genetic Testing is organized by existing fantastic and current market state of affairs.

The key makers of Preimplantation Genetic Testing enclosed within the reports are:

Perkinelmer, Rubicon Genomics, Scigene, Illumina, Gen, Agilent Technologies, Oxford Gene Technology, Beijing Genomics Institute, Abbott Laboratories, Good Start Genetics, Combimatrix, Yikon Genomics, Thermo Fisher, Natera, Coopersurgical and Invicta Genetics

Market Segment By Types:

Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening

Market Segment By Applications :

Hospitals, Maternity Centers & Fertility Clinics, Research Laboratories & Academic Institutes, and Service Providers and Diagnostic Labs

Key Regions split during this report:

North America (the USA, North American country and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (India, China, Japan, Korea and Southeast Asia)

South America ( Columbia, Brazil, Argentinaetc.)

The Middle East and continent (Saudi Arabian Peninsula, UAE, Egypt, African country and South Africa)

To Purchase The Report Click Here:https://market.us/purchase-report/?report_id=12405

Key Reasons to shop for the report:

-To induce a discriminating survey of preimplantation genetic testing market and have the numerous that means of the worldwide Preimplantation Genetic Testing market and its comprehensive landscape.

-Assess international preimplantation genetic testing market production processes, major issues, and solutions to decrease the expansion risk.

-To know the foremost vast drives and restraint forces in Preimplantation Genetic Testing Market and its collision within the international market.

-To own the summary regarding preimplantation genetic testing market methods that are being applied by leading various industries.

-To know the excellent outlook and prospects for preimplantation genetic testing market.

-Save and decrease time carrying out entry-level research by identifying the growth, size, major players and segments in the global preimplantation genetic testing market

-Highlights key business significances and priorities in order to support companies to rearrange their business strategies.

-The key findings and proposals highlight crucial progressive industry trends in the Preimplantation Genetic Testing Market, thereby allowing players to develop effective long-term strategies.

-Develop or modify business development plans by using considerable growth offering developed and emerging markets.

-Examine in-depth global preimplantation genetic testing market trends and outlook coupled with the factors driving the market, as well as those hindering it.

-Improve the decision-making process by understanding the strategies that support commercial credit with respect to products, segmentation and industry verticals.

Get in-depth analysis of the COVID-19 impact on the Preimplantation Genetic Testing Market :https://market.us/report/preimplantation-genetic-testing-market//#inquiry

Lastly, the preimplantation genetic testing report offers market size and estimates for the period from 2019 to 2028, keeping in mind the above-mentioned factors. This report will be helpful for preimplantation genetic testing vendors, system integrators, and related business partners to understand key investment areas and define their strategies. In addition, this analysis study covers intensive research of various market sections based on applications, study across completely different geographies and products.

Why Go For Market.us Research?

Market.US specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons. We offer tactical and strategic support, which enables our esteemed clients to make well-informed business decisions and chart out future plans and attain success every single time. Besides analysis and scenarios, we provide insights into global, regional, and country-level information and data, to ensure nothing remains hidden in any target market. Our team of tried and tested individuals continues to break barriers in the field of market research as we forge forward with a new and ever-expanding focus on emerging markets.

Get in Touch with Us :

Mr. Benni Johnson

Market.us (Powered By Prudour Pvt. Ltd.)

Send Email:inquiry@market.us

Address:420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Tel:+1 718 618 4351

Website:https://market.us

See more here:
New Research on Preimplantation Genetic Testing Market by Trending Key players-Illumina, Thermo Fisher, Agilent Technologies - Galus Australis

Recommendation and review posted by Bethany Smith

An Owensboro woman recently discovered a big sister she never knew she had living in Germany. Randi Caldwell and Crimson Smith are meeting for the first time later this year after finding each other through genetic testing.

Caldwells mother died when she was very young, and now as a mother herself, she wanted to learn more about her history and heritage for her own daughter.

So Caldwell purchased a 23andMe DNA kit to learn more. Her initial results were nothing unexpected, but this spring she received the surprise of a lifetime a message from a woman matched with her as a half-sister.

Caldwell said as she was growing up she lost her family one at a time. Her mother died when she was 4 and the man she thought was her father died in 2010, and she was then raised by his parents. They passed away when she was a teenager, and Caldwell bounced around from state to state for a while.

I learned during this time that my dad wasnt my real father, but because my mother was deceased no one had any idea of who he may be, other than she once mentioned he lived in Georgia, she said.

In 2019 at 30 years old and as a single mom, Caldwell decided to find out more.

I wanted to see if I could learn anything about my family by doing a DNA test, she said. This was my only option because no family members were left. I got my results and lots of second- and third-cousins, but none that I recognized. I did learn a lot about my medical history, which I was happy about.

In March of this year, Calwell woke up to a message on the 23andMe app from a female in Germany.

She said that she had taken the test and it claimed we were half-sisters, Caldwell said. She asked me if there was any way it could be true.

Caldwell said it took her a few moments to gather her thoughts but she messaged back and then waited.

I did some digging and found her on social media, Caldwell said. When I looked at her photos I was shocked at how we looked so much alike.

Smith is 16 years older than Caldwell, and together they figured out that their shared father met Caldwells mother while on vacation.

Caldwell was thrilled to find out the identity of her birth father, though disappointed to learn he died before the age of 50 from heart disease. However, she was glad to learn about this important health history for herself and her daughter.

Caldwell and Smith message constantly now that they have connected. Smith is based in Germany with the military and is hoping to visit the U.S. this summer to meet in-person for the first time.

Its strange to see pictures of an entire family that look just like me, Caldwell said. Im excited for the future and what it holds.

Go here to see the original:
DNA testing connects Owensboro woman to half-sister in Germany - The Owensboro Times

Recommendation and review posted by Bethany Smith

New Jersey, United States,- The latest research study on Preimplantation Genetic Testing Market Added by Verified Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Preimplantation Genetic Testing market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

Global Preimplantation Genetic Testing Market was valued at USD 306.16 million in 2016 and is projected to reach USD 701.49 million by 2025, growing at a CAGR of 9.65% from 2017 to 2025.

Download Sample Copy of Preimplantation Genetic Testing Market Report Study 2020-2027 @ https://www.verifiedmarketresearch.com/download-sample/?rid=24037&utm_source=APS&utm_medium=007

The research report on the Preimplantation Genetic Testing market provides a granular assessment of this business vertical and includes information concerning the market tendencies such as revenue estimations, current remuneration, market valuation, and market size over the estimated timeframe.

Major Players Covered in this Report are:

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Preimplantation Genetic Testing market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

The scope of the Report:

The report segments the global Preimplantation Genetic Testing market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritty of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also addresses political scenarios that are expected to impact the market in both small and big ways. The report on the global Preimplantation Genetic Testing market examines changing regulatory scenarios to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Discount on Preimplantation Genetic Testing Market Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24037&utm_source=APS&utm_medium=007

As per the regional scope of the Preimplantation Genetic Testing market:

Highlights of the report:

Key Questions Answered in the report:

Learn More about this report @ https://www.verifiedmarketresearch.com/product/Preimplantation-Genetic-Testing-Market/?utm_source=APS&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Cellular Health Screening-Health Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Preimplantation Genetic Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Cell Based Assays Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Protein Expression Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Analytical Standards Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Originally posted here:
Preimplantation Genetic Testing Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 - Apsters News

Recommendation and review posted by Bethany Smith

BEIJING, June 30, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, Nasdaq: GTH), a leading precision oncology platform company that covers full-cycle cancer care, presented data from 14 clinical research studies at theAmerican Association for Cancer Research (AACR) VirtualAnnual Meeting II held June 22 to 24. The presented data demonstrated the sensitivity and specificity of Genetrons industry-leading next generation sequencing (NGS) technologies utilized by cancer hospitals to detect genetic alterations for clinical management.

Data presented at the AACR Virtual Annual Meeting were generated in collaboration with more than 10 well-known cancer research institutions and hospitals in China. Genetrons innovative technologies, including library construction and enrichment, unknown gene fusion detection, and liquid biopsy testing, were featured in 14 clinical studies presented at the AACR meeting.

One-Step Seq Method for Library Construction and Enrichment

Genetrons One-Step Seq Method is specifically designed for small to medium size panels and simplifies the traditional labor intensive library construction/enrichment experiments to a single mixture of DNA sample to their reagent and one PCR reaction, minimizing hands-on time and risk of contamination and reducing the total time for library construction to 1.5 hours. The operational simplicity of this One-Step Seq Method makes it easier for hospitals to conduct the testing at a lower cost, thus yielding better profitability for hospitals.

Poster 743 presented the research teams development of an all-in-one panel for brain cancer based on the Companys patented One-Step Seq Method to detect glioma driver gene mutations and 1p/19q co-deletion, requiring less biopsy and highly consistent with current technologies such as qPCR and FISH[1].

Methylation of the MGMT gene promoter is a biomarker for increased sensitivity to alkylating agent-based chemotherapy. Poster 3186 presented how the team combined bisulfite conversion with amplicon sequencing of MGMT gene promoter based on One-Step Seq method to analyze MGMT promoter methylation status, the results of which were 94.4% consistent with the gold standard results[2].

New methodology for the discovery of novel gene fusion

Compared to single nucleotide polymorphism (SNPs), it is technically more challenging to detect gene fusions, in particular, novel unknown fusions. Poster 4149 presented the research teams development of an RNA-Capseq panel targeting 395 cancer genes to detect gene fusions. Lung cancer cell lines or hematological tumors with known fusion genes and the FFPE samples from 10 patients with unknown types of sarcoma were assessed. Compared with lncRNA-seq, the RNA-Capseq panel could pinpoint fusions with a relatively small amount of data, which makes it more affordable and accessible. Moreover, this method can identify fusions in cases of low tumor purity or poor RNA quality. Compared to FISH and RT-PCR, the RNA-Capseq panel can detect more fusion genes at one time, and also discover novel fusion subtypes[3].

Application of Liquid Biopsy Low-Frequency Mutation Detection Technology in clinical investigations

Genetron Health has launched several liquid biopsy-based tests for cancer diagnosis, early detection, and monitoring.

Poster 1991 presented a collaborative clinical study of neoadjuvant chemotherapy (NAC) treatment selection, in which a cohort of 25 patients with Stage II/III gastric adenocarcinoma after surgical treatment were enrolled. The research analyzed the mutation profiles of 50 plasma samples collected from the patients using its 179 cancer-related gene panel. Copy number instability (CNI) scores of ctDNA were calculated to reflect chromosome instability in ctDNA. The results indicated CNI score of pre- neoadjuvant chemotherapy (NAC) ctDNA is a potential biomarker of response and prognosis to NAC in gastric cancer patients before NAC treatment[4].

Leptomeningeal metastases (LM), associated with poor survival, were much more frequently detected in NSCLC patients harboring EGFR mutations. Though EGFR-TKIs therapy significantly increased overall survival, many patients inevitably develop acquired resistance. Poster 723 presented a study enrolling 31 lung adenocarcinoma patients harboring EGFR mutations, who had received at least 6 months of EGFR-TKIs treatment before the diagnosis of LM. The research collected 10 ml of CSF and matched 10 ml peripheral blood. The results suggested that, during EGFR-TKIs treatment, the acquired resistance mutations in the LM for NSCLC patients were independent from those in extracranial lesions[5].

Currently, ureteroscopy is commonly used in pathological tests before surgery. However, in addition to the trauma and infection risks attached to ureteroscopy, the possibility of exudation and adhesion of surrounding tissues significantly increased after the process. Hypertension in the cavity may cause tumor spread, and the use of ureteroscopy and biopsy may cause the recurrence of bladder tumors after surgery. The poster 2293 presented a study where urine from 150 hematuria patients with upper tract urinary disease and 100 healthy people were assessed. The liquid biopsy assay tested demonstrated a sensitivity of 94% and a specificity of 96% in cancer detection[6]. Meanwhile, poster 2296 presented a study that assessed urine from 109 hematuria patients with upper tract urinary disease, in which the liquid biopsy assay demonstrated a sensitivity of 83.5%, a specificity of 90%, NPV of 67.5%, and PPV of 95.7% of detection of cancers[7]. The urinary assays high sensitivity, high specificity, and non-invasiveness make it a potential clinical alternative to ureteroscopy.

Reference[1] Min Shi, Sumin Geng, et al. An amplicon sequencing based all-in-one genetic testing panel for molecular classification and guiding individualized treatment of brain cancer. Poster 743 presented at AACR Virtual Annual Meeting II, June 22-24, 2020.[2] Yukun Zhang, Min Shi, et al. Methylation MGMT gene promoter analysis based on a high throughput method combines bisulfite conversion with amplicon sequencing. Poster 3186 presented at AACR Virtual Annual Meeting II, June 22-24, 2020.[3] Gu Jin, Chunyang Wang, et al. Targeted RNA-Capseq provides new insight into clinical fusion detection. Poster 4149 presented at AACR Virtual Annual Meeting II, June 22-24, 2020.[4] Yongning Jia, Honglin Zhu, et al. Chromosomal Instability of Circulating tumor DNA Predicts Response to Neoadjuvant Chemotherapy In Gastric Cancer. Poster 1991 presented at AACR Virtual Annual Meeting II, June 22-24, 2020.[5] Xi Wu, Puyuan Xing, et al. Genetic profiling of cerebrospinal fluid cfDNA from NSCLC patients with leptomeningeal metastases reveals EGFR-TKIs resistant mutations independent of extracranial lesions (cases series). Poster 723 presented at AACR Virtual Annual Meeting II, June 22-24, 2020. [6] Yansheng Xu, Hongzhao Li, et al. A Urine-based liquid biopsy Method for Detection of upper tract urinary carcinoma. Poster 2293 presented at AACR Virtual Annual Meeting II, June 22-24, 2020.[7] Hu Qu, Yu Zeng, et al. A Multicenter, Prospective Evaluation of Urine-Based ctDNA Assay for Urinary Cancers Diagnosis. Poster 2296 presented at AACR Virtual Annual Meeting II, June 22-24, 2020.

About Genetron HealthGenetron Holdings Limited (Genetron Health, Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care.

Forward-looking StatementsThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of Genetron Healths One-Step Seq Method, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such risks and uncertainties include those discussed under the caption Risk Factors in Genetron Healths filings with the Securities and Exchange Commission. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Genetron Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Genetron Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Genetron Healths views as of any date subsequent to the date of this press release. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Genetron Health.

Investor Relations Contact:Stephanie CarringtonWestwicke, an ICR CompanyStephanie.Carrington@westwicke.comOffice: +1 (646) 277-1282

Asia:Bill ZimaICR, Inc.Email: bill.zima@icrinc.comir@genetronhealth.com

Media Relations Contact:Edmond LococoICR, Inc. Edmond.Lococo@icrinc.comMobile: +86 138-1079-1408pr@genetronhealth.com

Read more from the original source:
Genetron Health Presents Cancer Clinical Research Data at AACR Virtual Annual Meeting Highlighting the Sensitivity and Specificity of its NGS...

Recommendation and review posted by Bethany Smith

The market research report published by QYResearch is a brilliant, in-depth, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Point-of-Care Genetic Testing market. It informs readers about key trends and opportunities in the global Point-of-Care Genetic Testing market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Point-of-Care Genetic Testing market.

Key companies operating in the global Point-of-Care Genetic Testing market include , Abbott (US), Roche (Switzerland), Thermo Fisher Scientific (US), Cepheid (US), IQuum (US), Biocartis (Switzerland), Idaho Technologies (US), Optigene (UK), Lumora (UK) Point-of-Care Genetic Testing

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1528785/global-point-of-care-genetic-testing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Point-of-Care Genetic Testing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Point-of-Care Genetic Testing Market Segment By Type:

, POCT Cancer Kits, Molecular POC Kits, POCT In Antibiotic Therapies, Assay Cartridge, Other Point-of-Care Genetic Testing

Global Point-of-Care Genetic Testing Market Segment By Application:

, Diagnostic Labs, Bio-Pharmaceutical Industry, Academic Institutions, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Point-of-Care Genetic Testing market.

Key companies operating in the global Point-of-Care Genetic Testing market include , Abbott (US), Roche (Switzerland), Thermo Fisher Scientific (US), Cepheid (US), IQuum (US), Biocartis (Switzerland), Idaho Technologies (US), Optigene (UK), Lumora (UK) Point-of-Care Genetic Testing

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1528785/global-point-of-care-genetic-testing-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Point-of-Care Genetic Testing Revenue1.4 Market Analysis by Type1.4.1 Global Point-of-Care Genetic Testing Market Size Growth Rate by Type: 2020 VS 20261.4.2 POCT Cancer Kits1.4.3 Molecular POC Kits1.4.4 POCT In Antibiotic Therapies1.4.5 Assay Cartridge1.4.6 Other1.5 Market by Application1.5.1 Global Point-of-Care Genetic Testing Market Share by Application: 2020 VS 20261.5.2 Diagnostic Labs1.5.3 Bio-Pharmaceutical Industry1.5.4 Academic Institutions1.5.5 Other1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends by Regions2.1 Point-of-Care Genetic Testing Market Perspective (2015-2026)2.2 Point-of-Care Genetic Testing Growth Trends by Regions2.2.1 Point-of-Care Genetic Testing Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Point-of-Care Genetic Testing Historic Market Share by Regions (2015-2020)2.2.3 Point-of-Care Genetic Testing Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Point-of-Care Genetic Testing Market Growth Strategy2.3.6 Primary Interviews with Key Point-of-Care Genetic Testing Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Point-of-Care Genetic Testing Players by Market Size3.1.1 Global Top Point-of-Care Genetic Testing Players by Revenue (2015-2020)3.1.2 Global Point-of-Care Genetic Testing Revenue Market Share by Players (2015-2020)3.1.3 Global Point-of-Care Genetic Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Point-of-Care Genetic Testing Market Concentration Ratio3.2.1 Global Point-of-Care Genetic Testing Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Point-of-Care Genetic Testing Revenue in 20193.3 Point-of-Care Genetic Testing Key Players Head office and Area Served3.4 Key Players Point-of-Care Genetic Testing Product Solution and Service3.5 Date of Enter into Point-of-Care Genetic Testing Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Point-of-Care Genetic Testing Historic Market Size by Type (2015-2020)4.2 Global Point-of-Care Genetic Testing Forecasted Market Size by Type (2021-2026) 5 Point-of-Care Genetic Testing Breakdown Data by Application (2015-2026)5.1 Global Point-of-Care Genetic Testing Market Size by Application (2015-2020)5.2 Global Point-of-Care Genetic Testing Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Point-of-Care Genetic Testing Market Size (2015-2020)6.2 Point-of-Care Genetic Testing Key Players in North America (2019-2020)6.3 North America Point-of-Care Genetic Testing Market Size by Type (2015-2020)6.4 North America Point-of-Care Genetic Testing Market Size by Application (2015-2020) 7 Europe7.1 Europe Point-of-Care Genetic Testing Market Size (2015-2020)7.2 Point-of-Care Genetic Testing Key Players in Europe (2019-2020)7.3 Europe Point-of-Care Genetic Testing Market Size by Type (2015-2020)7.4 Europe Point-of-Care Genetic Testing Market Size by Application (2015-2020) 8 China8.1 China Point-of-Care Genetic Testing Market Size (2015-2020)8.2 Point-of-Care Genetic Testing Key Players in China (2019-2020)8.3 China Point-of-Care Genetic Testing Market Size by Type (2015-2020)8.4 China Point-of-Care Genetic Testing Market Size by Application (2015-2020) 9 Japan9.1 Japan Point-of-Care Genetic Testing Market Size (2015-2020)9.2 Point-of-Care Genetic Testing Key Players in Japan (2019-2020)9.3 Japan Point-of-Care Genetic Testing Market Size by Type (2015-2020)9.4 Japan Point-of-Care Genetic Testing Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Point-of-Care Genetic Testing Market Size (2015-2020)10.2 Point-of-Care Genetic Testing Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Point-of-Care Genetic Testing Market Size by Type (2015-2020)10.4 Southeast Asia Point-of-Care Genetic Testing Market Size by Application (2015-2020) 11 India11.1 India Point-of-Care Genetic Testing Market Size (2015-2020)11.2 Point-of-Care Genetic Testing Key Players in India (2019-2020)11.3 India Point-of-Care Genetic Testing Market Size by Type (2015-2020)11.4 India Point-of-Care Genetic Testing Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Point-of-Care Genetic Testing Market Size (2015-2020)12.2 Point-of-Care Genetic Testing Key Players in Central & South America (2019-2020)12.3 Central & South America Point-of-Care Genetic Testing Market Size by Type (2015-2020)12.4 Central & South America Point-of-Care Genetic Testing Market Size by Application (2015-2020) 13 Key Players Profiles13.1 Abbott (US)13.1.1 Abbott (US) Company Details13.1.2 Abbott (US) Business Overview and Its Total Revenue13.1.3 Abbott (US) Point-of-Care Genetic Testing Introduction13.1.4 Abbott (US) Revenue in Point-of-Care Genetic Testing Business (2015-2020))13.1.5 Abbott (US) Recent Development13.2 Roche (Switzerland)13.2.1 Roche (Switzerland) Company Details13.2.2 Roche (Switzerland) Business Overview and Its Total Revenue13.2.3 Roche (Switzerland) Point-of-Care Genetic Testing Introduction13.2.4 Roche (Switzerland) Revenue in Point-of-Care Genetic Testing Business (2015-2020)13.2.5 Roche (Switzerland) Recent Development13.3 Thermo Fisher Scientific (US)13.3.1 Thermo Fisher Scientific (US) Company Details13.3.2 Thermo Fisher Scientific (US) Business Overview and Its Total Revenue13.3.3 Thermo Fisher Scientific (US) Point-of-Care Genetic Testing Introduction13.3.4 Thermo Fisher Scientific (US) Revenue in Point-of-Care Genetic Testing Business (2015-2020)13.3.5 Thermo Fisher Scientific (US) Recent Development13.4 Cepheid (US)13.4.1 Cepheid (US) Company Details13.4.2 Cepheid (US) Business Overview and Its Total Revenue13.4.3 Cepheid (US) Point-of-Care Genetic Testing Introduction13.4.4 Cepheid (US) Revenue in Point-of-Care Genetic Testing Business (2015-2020)13.4.5 Cepheid (US) Recent Development13.5 IQuum (US)13.5.1 IQuum (US) Company Details13.5.2 IQuum (US) Business Overview and Its Total Revenue13.5.3 IQuum (US) Point-of-Care Genetic Testing Introduction13.5.4 IQuum (US) Revenue in Point-of-Care Genetic Testing Business (2015-2020)13.5.5 IQuum (US) Recent Development13.6 Biocartis (Switzerland)13.6.1 Biocartis (Switzerland) Company Details13.6.2 Biocartis (Switzerland) Business Overview and Its Total Revenue13.6.3 Biocartis (Switzerland) Point-of-Care Genetic Testing Introduction13.6.4 Biocartis (Switzerland) Revenue in Point-of-Care Genetic Testing Business (2015-2020)13.6.5 Biocartis (Switzerland) Recent Development13.7 Idaho Technologies (US)13.7.1 Idaho Technologies (US) Company Details13.7.2 Idaho Technologies (US) Business Overview and Its Total Revenue13.7.3 Idaho Technologies (US) Point-of-Care Genetic Testing Introduction13.7.4 Idaho Technologies (US) Revenue in Point-of-Care Genetic Testing Business (2015-2020)13.7.5 Idaho Technologies (US) Recent Development13.8 Optigene (UK)13.8.1 Optigene (UK) Company Details13.8.2 Optigene (UK) Business Overview and Its Total Revenue13.8.3 Optigene (UK) Point-of-Care Genetic Testing Introduction13.8.4 Optigene (UK) Revenue in Point-of-Care Genetic Testing Business (2015-2020)13.8.5 Optigene (UK) Recent Development13.9 Lumora (UK)13.9.1 Lumora (UK) Company Details13.9.2 Lumora (UK) Business Overview and Its Total Revenue13.9.3 Lumora (UK) Point-of-Care Genetic Testing Introduction13.9.4 Lumora (UK) Revenue in Point-of-Care Genetic Testing Business (2015-2020)13.9.5 Lumora (UK) Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original here:
Trending: Point-of-Care Genetic Testing Market: Reporting and Evaluation of Recent Industry Developments| Abbott (US), Roche (Switzerland), Thermo...

Recommendation and review posted by Bethany Smith

Hematopoietic stem cell transplantation is a curative therapy for many patients suffering from life threatening blood disorders. This treatment is currently limited by the availability of compatible bone marrow donors and, as a result, transplant of unrelated donor umbilical cord blood is an attractive alternative.This approach has the advantages of rapid availability and reduced stringency for a complete donor/recipient match, but is limited by a relatively low number of stem cells within a single cord blood unit. One focus of the Stem Cell Regulators research group, led by Prof. Jonas Larsson, is the development of new strategies to expand stem cells ex vivo, allowing for the treatment of patients who otherwise would lack a suitable donor.

When grown outside the body hematopoietic stem cells proliferate and differentiate from an immature state to more mature blood cell types. explains Prof. Larsson. We aim to identify novel ways to counteract this maturation, pushing stem cells to self-renew and increase in numbers.

In a study published in the journal Blood, the Larsson group targeted the enzyme LSD1, part of the CoREST complex, known to mediate the epigenetic modification of DNA and pushing the differentiation of stem cells into mature blood cells.

We hypothesised that by reducing LSD1 levels using small molecule drugs we could halt stem cell differentiation and stimulate expansion. explains postdoctoral researcher Agatheeswaran Subramaniam and first author on the paper.

This turned out to be the case for both cord blood derived and adult bone marrow stem cells, with LSD1 inhibition expanding stem and progenitor cells from different sources and different stages of development.

To gain insights into how targeting LSD1 led to the expansion of stem cells, the group performed gene expression profiling. They compared LSD1 inhibition to treatment with UM171, a human hematopoietic stem cell promoting molecule identified in 2014 and currently in phase II clinical trials, despite an as yet unidentified mechanism of action. The gene signatures of LSD1 inhibition and UM171 treatment were strikingly similar.

The research group then postulated that these treatments could be working by the same mechanism.

Through a collaboration with Prof. Roman Zubarev at Karolinska Institute, the key targets of UM171 were established using a technique known as Thermal Proteome Profiling. This approach, which identifies interactions between small molecules and proteins, confirmed the direct binding of UM171 to LSD1, as well as to the core structural component of the CoREST complex, RCOR1.

Extensive analyses by Kristijonas emaitis, a PhD student in the Larsson lab, revealed that UM171 directs the components of the CoREST complex to degradation via the ubiquitin proteasome pathway, the system used by the cell to break down proteins.

In this study have we identified a novel target for human hematopoietic stem cell expansion ex vivo, as well as taking steps to understanding the previously undetermined mechanism of action of UM171. reflects Agatheeswaran. The most striking finding was the extremely rapid and efficient degradation of members of the CoREST complex by UM171.

What remains unclear is exactly how the CoREST complex is targeted and its degradation triggered. An understanding of this has the potential to reveal principles that can be exploited for purposes not only limited to stem cell expansion.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See more here:
New Insights Into the Ex Vivo Expansion of Transplantable Human Blood Stem Cells - Technology Networks

Recommendation and review posted by Bethany Smith

Hematopoietic Stem Cells Transplantation (HSCT) Market report provides (6 Year Forecast 2020-2026) including detailed Coronavirus (COVID-19) impact analysis on Market Size, Regional and Country-Level Market Size, Segmentation Market Growth, Market Share, Competitive Landscape, Sales Analysis and Value Chain Optimization. This Hematopoietic Stem Cells Transplantation (HSCT) market competitive landscape offers details by topmost key manufactures (Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems) including Company Overview, Company Total Revenue (Financials), Market Potential, Presence, Hematopoietic Stem Cells Transplantation (HSCT) industry Sales and Revenue Generated, Market Share, Price, Production Sites and Facilities, SWOT Analysis, Product Launch. For the period 2014-2020, this study provides the Hematopoietic Stem Cells Transplantation (HSCT) sales, revenue and market share for each player covered in this report.

Key Target Audience of Hematopoietic Stem Cells Transplantation (HSCT) Market: Manufacturers of Hematopoietic Stem Cells Transplantation (HSCT), Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Hematopoietic Stem Cells Transplantation (HSCT) market.

Get Free Sample PDF (including COVID-19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cells Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2039940

Synopsis of Hematopoietic Stem Cells Transplantation (HSCT) Market:Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The indications for HSCT thus are wide; the most frequent indication as per reported by Worldwide Network for Blood and Marrow Transplantation Group (WNBT) (2013) is lymphoproliferative disorder (53.2% of all HSCT), 12% of whom received allogeneic and the rest received autologous transplant. Plasma cell disorders are the most frequent indication in this group. A multitude of literature published by researchers and organizations demonstrate that autologous transplant own a greater edge against allogeneic HSCT.

Over 30 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further application of this approach it may eventually be able to treat a wide array of conditions and replace ailing tissues. However, despite the vast experience with HSCs, researchers face major barriers in expanding their use beyond the replacement of immune and blood cells.

Hematopoietic stem cells are unable to proliferate and differentiate in-vitro. Researchers have yet to evolve an accurate method to differentiate stem cells from other cells derived from blood or bone marrow. Once such technical barriers are overcome, the avenues for realizing the full potential of HSCT. The type of transplant a person receives depends on several different factors, including the type and course of the disease, availability of suitable donors, and the patients overall health. There are three different sources of hematopoietic stem cells such as bone marrow, peripheral blood stem cells, and umbilical cord blood. The stem cell source used for a given transplant depends upon the underlying disease, the type of transplant (allogeneic or autologous), and size of the patient.

Based onProduct Type, Hematopoietic Stem Cells Transplantation (HSCT) market report displays the manufacture, profits, value, and market segment and growth rate of each type, covers:

Autologous Transplant Allogenic Transplant

Based onend users/applications, Hematopoietic Stem Cells Transplantation (HSCT) market report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, this can be divided into:

Leukemia Lymphoproliferative Disorders Solid Tumors Non-Malignant Disorders Others

Hematopoietic Stem Cells Transplantation (HSCT) Market: Regional analysis includes:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2039940

The Hematopoietic Stem Cells Transplantation (HSCT) Market Report Can Answer The Following Questions:

What are the Upstream Raw Materials And Manufacturing Equipment of Hematopoietic Stem Cells Transplantation (HSCT)? What is the manufacturing process of Hematopoietic Stem Cells Transplantation (HSCT)?

Who are the key manufacturers of Hematopoietic Stem Cells Transplantation (HSCT) market? How are their operating situation (Capacity, Production, Price, Cost, Gross and Revenue)?

Economic impact on Hematopoietic Stem Cells Transplantation (HSCT) industry and development trend of Hematopoietic Stem Cells Transplantation (HSCT) industry.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) Production, Production Value, Consumption, Consumption Value, Import And Export of Hematopoietic Stem Cells Transplantation (HSCT)?

What will the Hematopoietic Stem Cells Transplantation (HSCT) Market Size and The Growth Rate be in 2026?

What are the key market trends impacting the growth of the Hematopoietic Stem Cells Transplantation (HSCT) market?

What are the Hematopoietic Stem Cells Transplantation (HSCT) Market Challenges to market growth?

What are the types and applications of Hematopoietic Stem Cells Transplantation (HSCT)? What is the market share of each type and application?

What are the key factors driving the Hematopoietic Stem Cells Transplantation (HSCT) market?

What are the Hematopoietic Stem Cells Transplantation (HSCT) market opportunities and threats faced by the vendors in the Hematopoietic Stem Cells Transplantation (HSCT) market?

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the original post:
Hematopoietic Stem Cells Transplantation (HSCT) Market Key Manufactures And Chance Analysis-Kite Pharma, Thermo Fisher Scientific, CellGenix...

Recommendation and review posted by Bethany Smith